Supplementary material 6. Subgroup and meta-regression analysis results (Figures S35-106)




Figure S35 Subgroups analysis of objective response rate by KPS score




Figure S36 Meta-regression of objective response rate by KPS score




Figure S37 Subgroups analysis of disease control rate by KPS score




Figure S38 Meta-regression of disease control rate by KPS score




Figure S39 Subgroups analysis of neutropenia by KPS score




Figure S40 Meta-regression of neutropenia by KPS score




Figure S41 Subgroups analysis of gastrointestinal reaction by KPS score




Figure S42 Meta-regression of gastrointestinal reaction by KPS score

Study or Subgroup		Total	emcitabine and o Events		Weight	Odds Ratio M-H, Fixed, 95% C	Year	Odds Ratio M-H, Fixed, 95% CI
nticipated surviva								
ou,Y.2006	24	42	13	39	1.4%	2.67 [1.08, 6.58]		
hao,H.2008	11	30	6	20	1.1%	1.35 [0.40, 4.53]		
ang,Q.2008	23	30	11	27	0.6%	4.78 [1.52, 14.98]		
un,G.2008	17	33	15	30	1.8%	1.06 [0.40, 2.86]	2008	
hang, L.2009	15	32	14	31	1.8%	1.07 [0.40, 2.89]	2009	
/en,K.2009	16	38	15	38	2.1%	1.12 [0.45, 2.79]		<u> </u>
v,D.2009	22	30	11	30	0.7%	4.75 [1.58, 14.25]		
ong,Z.2009	10	30	9	30	1.4%	1.17 [0.39, 3.47]	2009	
/ang,Y.2009	17	32	12	27	1.4%	1.42 [0.51, 3.96]	2009	
lou,A.2010	16	40	14	38	2.0%	1.14 [0.46, 2.85]	2010	
i,Z.2010	16	36	12	36	1.6%	1.60 [0.62, 4.16]		
iu,Y.2010	16	32	10	32	1.2%	2.20 [0.79, 6.10]		
hi,X.2010	13	28	10	28	1.3%	1.56 [0.53, 4.56]		
long,Y.2010	57	90	32	70	3.1%	2.05 [1.09, 3.88]	2010	
e,W.2011	15	29	10	23	1.3%	1.39 [0.46, 4.18]	2011	
an,S.2011	22	41	12	38	1.4%	2.51 [1.00, 6.29]	2011	•
ang,S.2011	15	32	12	30	1.6%	1.32 [0.48, 3.63]	2011	
ing,P.2011	9	18	10	22	1.1%	1.20 [0.34, 4.18]	2011	
hang,Y. 2012	21	41	15	42	1.7%	1.89 [0.78, 4.55]	2012	
un,J.2012	15	34	13	34	1.7%	1.28 [0.48, 3.36]	2012	
u, L.2012	19	35	16	35	1.7%	1.41 [0.55, 3.61]	2012	
/ang,Y.2012	16	36	14	36	1.8%	1.26 [0.49, 3.21]		
/ang,J.2012	14	25	10	24	1.1%	1.78 [0.57, 5.53]		
u,S.2013	19	34	12	34	1.3%	2.32 [0.87, 6.16]		+
, H.2014	16	30	12	30	1.3%	1.71 [0.62, 4.77]		
heng, B.2014	12	49	16	52	2.8%	0.73 [0.30, 1.76]		
ven, H.2014	28	45	17	45	1.5%	2.71 [1.16, 6.36]	2014	
i, J.2014	11	27	10	27	1.4%	1.17 [0.39, 3.49]	2014	
iu,Y.2014	18	43	17	43	2.3%	1.10 [0.47, 2.60]	2014	
hao, S.2015	19	43	12	43	1.6%	2.05 [0.83, 5.02]		+
hu, H.2015	15	21	7	21	0.5%	5.00 [1.35, 18.55]		
i, J.2016	23	47	9	47	1.1%	4.05 [1.61, 10.20]		
		25	8	25	0.5%			
hang, X.2016	18 19	33	19	35	1.9%	5.46 [1.63, 18.36]	2016 2016	
Ma, Y. 2016		30	13	30		1.14 [0.44, 2.98]		
hen, Y.2016	15				1.5%	1.31 [0.47, 3.61]		
Su, S.2017	35	40	23	39	0.7%	4.87 [1.57, 15.13]		
v, W.2018	16	30	15	30	1.7%	1.14 [0.41, 3.15]	2018	
hou, D.2018	30	58	22	58	2.5%	1.75 [0.84, 3.67]	2018	<u>-</u>
u,D.2019	30	41	17	41	1.1%	3.85 [1.52, 9.75]	2019	
hao,J.2019	31	43	22	43	1.5%	2.47 [1.01, 6.04]		
Seng,K.2020	27	45	17	45	1.6%	2.47 [1.06, 5.77]		
an, H.2020	24	60	18	60	2.6%	1.56 [0.73, 3.31]	2020	
Subtotal (95% CI)		1558		1508	64.1%	1.81 [1.56, 2.09]		\
otal events leterogeneity: Chi² =	825		582					
est for overall effect	ıl time(≥5mo	onth)		24	1.00/	4 42 10 42 2 041	2011	
.u,Z.2011	18	34	17 15	34	1.9%	1.13 [0.43, 2.91]		
i, Jc.2016	21	35	15	35	1.4%	2.00 [0.77, 5.18]		
luang, W.2017	17	39	11	40	1.5%	2.04 [0.80, 5.21]		
la, M.2017		42	12	42	1.6%	2.07 [0.84, 5.10]		<u> </u>
	19				1.2%			
	19 25	40	14	40		3.10 [1.24, 7.71]	2020	
ubtotal (95% CI)	25	40 190		40 191	7.6%	3.10 [1.24, 7.71] 1.98 [1.31, 3.00]	2020	•
ubtotal (95% CI) otal events	25 100	190	69				2020	•
ubtotal (95% CI) otal events eterogeneity: Chi ² = est for overall effect	25 100 = 2.29, df = 4 t: Z = 3.24 (P	190 (P = 0.68) = 0.001)	69				2020	
(u,Z.2020 subtotal (95% CI) otal events leterogeneity: Chi ² = est for overall effect Anticipated surviva	25 100 = 2.29, df = 4 t: Z = 3.24 (P	190 (P = 0.68) = 0.001) ar)	69); I² = 0%	191	7.6%	1.98 [1.31, 3.00]		
subtotal (95% CI) otal events leterogeneity: Chi ² = est for overall effect	25 100 = 2.29, df = 4 t: Z = 3.24 (P	190 (P = 0.68) = 0.001)	69					
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008	25 100 = 2.29, df = 4 t: Z = 3.24 (P	190 (P = 0.68) = 0.001) ar)	69); I² = 0%	191	7.6%	1.98 [1.31, 3.00]	2008	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect inticipated surviva eng,X.2008 /u,Q.2011	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle: 30	190 (P = 0.68) = 0.001) ar) 68	69); I² = 0%	191	7.6% 3.5%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35]	2008 2011	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Unclead) 30 17	190 (P = 0.68) = 0.001) ar) 68 30	69); I ² = 0% 25 11	191 62 30	7.6% 3.5% 1.1%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36]	2008 2011 2012	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng, X.2008 /u, Q.2011 u, Y.2012 ei, W.2012	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle 30 17 16	190 (P = 0.68) = 0.001) ar) 68 30 33	69 (; ² = 0% 25 11 16	62 30 33	7.6% 3.5% 1.1% 2.0%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63]	2008 2011 2012 2012	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle: 30 17 16 15	190 (P = 0.68) = 0.001) ar) 68 30 33 40	69); I ² = 0% 25 11 16 11	62 30 33 40	3.5% 1.1% 2.0% 1.6%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07]	2008 2011 2012 2012 2013	
ubtotal (95% CI) otal events leterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Unclession) 17 16 15 19	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38	69 25 11 16 11 18	62 30 33 40 42 70	3.5% 1.1% 2.0% 1.6% 2.0% 3.4%	1.98 [1.31, 3.00] 1.17 [0.58, 2.36] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.35 [0.68, 2.67]	2008 2011 2012 2012 2013 2013	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 an, R.2015	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle 30 17 16 15 19 45	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70	69 25 11 16 11 18 40	62 30 33 40 42	3.5% 1.1% 2.0% 1.6% 2.0%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45]	2008 2011 2012 2012 2013 2013	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng, X.2008 /u,G.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 ai,L.2015 hang, M.2015	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle: 30 17 16 15 19 45 14 17	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39	69 1); I ² = 0% 25 11 16 11 18 40 10 12	62 30 33 40 42 70 36 32	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.4% 1.8%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.35 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35]	2008 2011 2012 2012 2013 2013 2015 2015	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 an, R.2015 hang, M.2015 ing, S.2015	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle: 30 17 16 15 19 45 14 17 19	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31	69 1; I ² = 0% 25 11 16 11 18 40 10 12	62 30 33 40 42 70 36 32 31	3.5% 1.1% 2.0% 1.4% 1.4% 1.8% 1.0%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07]	2008 2011 2012 2012 2013 2013 2015 2015 2015	
ubtotal (95% CI) total events eterogeneity: Chi² = est for overall effect unticipated surviva eng.X.2008 I/u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 an, R.2015 hang, M.2015 hang, S.2016	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle: 30 17 16 15 19 45 14 17 19 11	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19	69 1; I ² = 0% 25 11 16 11 18 40 10 12 11 8	62 30 33 40 42 70 36 32 31	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.4% 1.8% 1.0% 0.8%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.35 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85]	2008 2011 2012 2012 2013 2013 2015 2015 2015 2016	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng, X.2008 /u,G.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 an, R.2015 hang, M.2015 ing, S.2016 ang, L.2016 ang, L.2016	25 100 = 2.29, df = 4 t: Z = 3.24 (P al time(Uncle: 30 17 16 15 19 45 14 17 19 11 35	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45	69 (; I² = 0%) 25 11 16 11 18 40 10 12 11 8 27	62 30 33 40 42 70 36 32 31 19	3.5% 1.1% 2.0% 1.6% 3.4% 1.4% 1.8% 1.0%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.63 [0.55, 3.22] 1.35 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87]	2008 2011 2012 2012 2013 2013 2015 2015 2015 2016 2016	
ubtotal (95% CI) otal (95% CI) otal events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 an, R.2015 hang, M.2015 hang, S.2016 hang, L.2016 hang, H.2017	25 100 = 2.29, df = 4 i: Z = 3.24 (P al time(Uncle. 30 17 16 15 19 45 14 17 19 11 35 42	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52	69 1; I ² = 0% 25 11 16 11 18 40 10 12 11 8 27 26	62 30 33 40 42 70 36 32 31 19 45 52	3.5% 1.1% 2.0% 1.6% 3.4% 1.4% 1.0% 0.8%	1.98 [1.31, 3.00] 1.17 [0.58, 2.36] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11]	2008 2011 2012 2012 2013 2015 2015 2015 2016 2016 2017	
ubtotal (95% CI) total events eterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 an, R.2015 hang, M.2015 ing, S.2015 hang, S.2016 ang, L.2016 ang, L.2017 /u, T.2017	25 100 100 100 11 = 2.29, df = 4 12 = 3.24 (P 11 itime(Uncle. 30 17 16 15 19 45 14 17 19 11 35 42 53	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67	69 1; I ² = 0% 25 11 16 11 18 40 10 12 11 8 27 26 40	62 30 33 40 42 70 36 32 31 19 45 52 68	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.4% 1.0% 0.8% 1.4% 1.2% 2.0%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68]	2008 2011 2012 2012 2013 2015 2015 2015 2016 2016 2017 2017	
ubtotal (95% CI) otal events leterogeneity: Chi² = est for overall effect unticipated surviva eng.X.2008 Vu.Q.2011 vu.Y.2012 ei, W.2012 vu, H.2013 ai,L.2013 ain, R.2015 hang, M.2015 ling, S.2016 hang, L.2016 hang, L.2016 hang, L.2017 vu, T.2017 vu, T.2017 vu, H.2019	25 100 = 2.29, df = 4 t: Z = 3.24 (P 101 102 103 104 105 105 106 105 107 107 108 109 109 109 109 109 109 109 109	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44	69 5; I ² = 0% 25 11 16 11 18 40 10 12 11 8 27 26 40	62 30 33 40 42 70 36 32 31 19 45 52 68	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.8% 1.0% 0.8% 1.4% 1.2% 1.6%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.63 [0.55, 3.22] 1.35 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019	
ubtotal (95% CI) otal (95% CI) teleprogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 Vu,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ain, R.2015 hang, M.2015 ing, S.2016 hang, L.2016 hang, H.2017 Vu, T.2017 iu, H.2019 ihen,C.2020	25 100 = 2.29, df = 4 i: Z = 3.24 (P a) 1 16 15 19 45 14 17 19 11 35 42 53 19 26	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49	69 0; I ² = 0% 25 11 16 11 18 40 10 12 11 8 27 26 40 12 16	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49	3.5% 1.1% 2.0% 1.6% 2.0% 1.4% 1.8% 1.2% 2.0% 1.6%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) otal events letterogeneity: Chi² = est for overall effect unticipated surviva eng.X.2008 /w.G.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 lan, R.2015 hang, M.2015 ling, S.2015 hang, L.2016 hang, H.2017 iu, H.2019 ethen,C.2020 u, Y.2020	25 100 = 2.29, df = 4 t: Z = 3.24 (P 101 102 103 104 105 105 106 105 107 107 108 109 109 109 109 109 109 109 109	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49 45	69 5; I ² = 0% 25 11 16 11 18 40 10 12 11 8 27 26 40	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49 45	3.5% 1.1% 2.0% 1.6% 3.4% 1.8% 0.8% 1.4% 1.2% 2.0% 1.6% 1.8%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.53 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29] 1.52 [0.62, 3.73]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) otal events eterogeneity: Chi² = est for overall effect enticipated surviva eng, X.2008 fu, Q.2011 u, Y.2012 ei, W.2012 u, H.2013 ai, L.2013 an, R.2015 hang, M.2015 ing, S.2016 ang, L.2016 hang, H.2017 fu, T.2017 u, H.2019 hen, C.2020 u, Y.2020 ubtotal (95% CI)	25 100 = 2.29, df = 4 t: Z = 3.24 (P 101 102 103 104 105 105 106 105 107 108 109 109 109 109 109 109 109 109	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49	69 1; I² = 0% 25 11 16 11 18 40 10 12 11 8 27 26 40 12 16	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49	3.5% 1.1% 2.0% 1.6% 2.0% 1.4% 1.8% 1.2% 2.0% 1.6%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) otal events letterogeneity: Chi² = est for overall effect unticipated surviva eng.X.2008 W.Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 an, R.2015 hang, M.2015 ling, S.2016 hang, H.2017 iu, H.2019 chen.C.2020 u, Y.2020 ubtotal (95% CI) otal events letterogeneity: Chi² =	25 100 = 2.29, df = 4 I: Z = 3.24 (P II time(Uncle. 30 16 15 19 45 14 17 19 11 35 42 53 19 26 16 16 15 16 17 19 10 11 11 12 13 14 15 16 16 16 16 16 16 16 16 16 16	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49 45 706	69 11 16 11 16 11 18 40 10 12 11 8 27 26 40 12 16 12 17 18 27 26 40 12 15 16 17 18 27 26 27 27 28 29 29 29 29 29 29 29 29 29 29	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49 45	3.5% 1.1% 2.0% 1.6% 3.4% 1.8% 0.8% 1.4% 1.2% 2.0% 1.6% 1.8%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.53 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29] 1.52 [0.62, 3.73]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) otal events leterogeneity: Chi² = est for overall effect unticipated surviva eng,X.2008 /u,Q.2011 u,Y.2012 ei, W.2012 u, H.2013 ai,L.2013 lan, R.2015 hang, M.2015 hang, S.2016 hang, L.2016 hang, L.2016 hen,C.2020 u, Y.2020 uuthotal (95% CI) otal events leterogeneity: Chi² = est for overall effect	25 100 = 2.29, df = 4 : Z = 3.24 (P 100 101 101 101 101 101 101 10	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49 45 706	69 11 16 11 16 11 18 40 10 12 11 8 27 26 40 12 16 12 17 18 27 26 40 12 15 16 17 18 27 26 27 27 28 29 29 29 29 29 29 29 29 29 29	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49 45 698	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.4% 1.0% 0.8% 1.4% 1.2% 2.0% 1.8% 2.84%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.35 [0.68, 2.67] 1.55 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.99 [0.52, 6.85] 2.33 [0.93, 5.87] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29] 1.52 [0.62, 3.73] 1.80 [1.45, 2.24]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) obtal events beterogeneity: Chi² = sast for overall effect nticipated surviva ang.X.2008 u,Q.2011 u,Y.2012 si, W.2012 u,H.2013 si,L.2013 si,L.2013 si,L.2015 ang, R.2015 nang, M.2015 nang, M.2016 ang, L.2017 u, H.2017 u, H.2017 u, H.2017 u, H.2017 u, H.2019 betal (95% CI) obtal events esterogeneity: Chi² = sast for overall effect obtal (95% CI)	25 100 = 2.29, df = 4 t: Z = 3.24 (P till time(Uncle. 30 17 16 15 19 45 14 17 19 11 35 42 15 33 19 26 6 16 16 15 5 16 16 17 17 19 17 17 19 18 17 17 19 18 18 18 18 18 18 18 18 18 18 18 18 18	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49 45 706 15 (P = 0.7 < 0.00001	69 11 16 11 18 40 10 12 11 8 27 26 40 12 16 12 16 17 18 19 19 10 11 11 11 12 11 11 12 13 14 15 16 17 18 18 19 19 19 19 19 19 19 19 19 19	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49 45 698	3.5% 1.1% 2.0% 1.6% 3.4% 1.8% 0.8% 1.4% 1.2% 2.0% 1.6% 1.8%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.53 [0.55, 3.22] 1.55 [0.68, 2.67] 1.65 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.89 [0.52, 6.85] 2.33 [0.93, 5.87] 4.20 [1.75, 10.11] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29] 1.52 [0.62, 3.73]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) obtal (95% CI) obtal (95% CI) obtal events beterogeneity: Chi² = sst for overall effect nticipated surviva ang, X.2008 u,Q.2011 u,Y.2012 u, W.2012 u, H.2013 an, R.2015 ang, S.2016 ang, S.2016 ang, S.2016 ang, L.2017 u, T.2017 u, H.2017 u, H.2017 u, H.2019 beterogeneity: Chi² = steforogeneity: Chi² = ste	25 100 = 2.29, df = 4 1: Z = 3.24 (P 101 102 103 104 105 105 106 105 107 109 109 109 109 109 109 109 109	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49 45 706	69 1; I ² = 0% 25 11 16 11 18 40 10 12 11 8 27 26 40 12 16 12 16 17 18 40 19 10 10 10 10 10 10 10 10 10 10	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49 45 698	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.4% 1.0% 0.8% 1.4% 1.2% 2.0% 1.8% 2.84%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.35 [0.68, 2.67] 1.55 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.99 [0.52, 6.85] 2.33 [0.93, 5.87] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29] 1.52 [0.62, 3.73] 1.80 [1.45, 2.24]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	
ubtotal (95% CI) bital events sterogeneity: Chi² = stst for overall effect nticipated surviva ng.X.2008 u,C.2011 u,Y.2012 sl, W.2012 u,Y.2013 sl, L.2013 si,L.2013 si,L.2013 si,L.2015 nang, M.2015 ng, S.2016 ng, L.2016 ng, L.2016 ng, L.2017 u, T.2017 u,	25 100 = 2.29, df = 4 I: Z = 3.24 (P 101 101 101 101 101 101 101 10	190 (P = 0.68) = 0.001) ar) 68 30 33 40 38 70 36 39 31 19 45 52 67 44 49 45 706 15 (P = 0.7 2454 62 (P = 0.7	69 15; I ² = 0% 25 11 16 11 18 40 10 12 11 18 27 26 40 12 16 11 12 27 26 40 12 15 16 17 18 40 40 10 10 11 11 12 13 14 15 16 17 17 18 19 19 19 19 19 19 19 19 19 19	62 30 33 40 42 70 36 32 31 19 45 52 68 44 49 45 698	3.5% 1.1% 2.0% 1.6% 2.0% 3.4% 1.4% 1.0% 0.8% 1.4% 1.2% 2.0% 1.8% 2.84%	1.98 [1.31, 3.00] 1.17 [0.58, 2.35] 2.26 [0.80, 6.36] 1.00 [0.38, 2.63] 1.58 [0.62, 4.07] 1.33 [0.55, 3.22] 1.35 [0.68, 2.67] 1.55 [0.61, 4.45] 1.29 [0.50, 3.35] 2.88 [1.03, 8.07] 1.99 [0.52, 6.85] 2.33 [0.93, 5.87] 2.65 [1.24, 5.68] 2.03 [0.83, 4.95] 2.33 [1.03, 5.29] 1.52 [0.62, 3.73] 1.80 [1.45, 2.24]	2008 2011 2012 2013 2013 2015 2015 2016 2016 2017 2017 2019 2020	0.01 0.1 1 10

Figure S43 Subgroups analysis of objective response rate by anticipated survival time




Figure S44 Meta-regression of objective response rate by anticipated survival time




Figure S45 Subgroups analysis of disease control rate by anticipated survival time




Figure S46 Meta-regression of disease control rate by anticipated survival time




Figure S47 Subgroups analysis of neutropenia by anticipated survival time




Figure S48 Meta-regression of neutropenia by anticipated survival time




Figure S49 Subgroups analysis of gastrointestinal reaction by anticipated survival time




Figure S50 Meta-regression of gastrointestinal reaction by anticipated survival time




Figure S51 Subgroups analysis of objective response rate by treatment process




Figure S52 Meta-regression of objective response rate by treatment process




Figure S53 Subgroups analysis of disease control rate by treatment process




Figure S54 Meta-regression of disease control rate by treatment process




Figure S55 Subgroups analysis of neutropenia by treatment process




Figure S56 Meta-regression of neutropenia by treatment process




Figure S57 Subgroups analysis of gastrointestinal reaction by treatment process




Figure S58 Meta-regression of gastrointestinal reaction by treatment process




Figure S59 Subgroups analysis of objective response rate by age




Figure S60 Meta-regression of objective response rate by age




Figure S61 Subgroups analysis of disease control rate by age




Figure S62 Meta-regression of disease control rate by age




Figure S63 Subgroups analysis of neutropenia by age




Figure S64 Meta-regression of neutropenia by age




Figure S65 Subgroups analysis of gastrointestinal reaction by age




Figure S66 Meta-regression of gastrointestinal reaction by age




Figure S67 Subgroups analysis of objective response rate by dosage of Aidi injection




Figure S68 Meta-regression of objective response rate by dosage of Aidi injection

kidi injection(50-60m eng,X.2008	Events	Total	Events	cisplatin Total	Weight	Odds Ratio M-H, Fixed, 95% CI Y	ear M-H, Fixed, 95% CI
		60		00	0.00/	4 44 10 04 0 00	
	62	68	56	62	2.3%	1.11 [0.34, 3.63] 2	
ong,Z.2009	27 32	30	25 32	30 38	1.1% 2.3%		109
en,K.2009	78	38 90	50	70	3.4%		110
ong,Y.2010 ou,A.2010	37	40	29	38	1.0%		110
ı,Y.2010	25	32	22	32	2.2%		110
i,X.2010	27	28	25	28	0.4%		110
n,S.2011	35	41	29	38	2.0%		111
i, W.2012	35	40	27	40	1.5%		112
	25	34	25	34	3.0%		
n,J.2012	20	25	16	24	1.5%	1.00 [0.34, 2.94] 2	
ng,J.2012							112
ang,Y. 2012	34	41	32	42	2.4%		112
L.2012	32	35	28	35	1.1%		112
H.2013	33	38	34	42	1.9%		13
L.2013	63	70	60	70	2.7%		113
5.2013	32	34	29	34	0.8%		13
Y.2014	35	43	33	43	2.8%		114
J.2014	19	27	16	27	2.1%		114
n, H.2014	43	45	36	45	0.7%		114
1.2014	26	30	23	30	1.4%		114
ng, M.2015	28	39	23	32	3.2%		15
g, S.2015	26	31	22	31	1.6%		15
ı, R.2015	32	36	27	36	1.3%		15
Y. 2016	28	33	28	35	1.9%		116
ng, S.2016	14	19	14	19	1.7%		116
g, L.2016	42	45	34	45	1.0%	4.53 [1.17, 17.55] 2	16
ng, X.2016	21	25	14	25	1.0%	4.13 [1.09, 15.59] 2	116
M.2017	37	42	29	42	1.6%	3.32 [1.06, 10.37] 2	17
S.2017	37	40	26	39	0.9%	6.17 [1.60, 23.83] 2	17
ing, W.2017	36	39	30	40	1.0%	4.00 [1.01, 15.87] 2	117
W.2018	24	30	25	30	2.2%		118
u, D.2018	50	58	38	58	2.4%		118
o,J.2019	39	43	34	43	1.4%	2.58 [0.73, 9.14] 2	
H.2019	39	44	30	44	1.5%	3.64 [1.18, 11.23] 2	19
n, H.2020	49	60	39	60	3.2%	2.40 [1.03, 5.57] 2	20
Y.2020	43	45	33	45	0.7%		20
ng,K.2020	39	45	31	45	1.9%		20
btotal (95% CI)		1503		1471	65.0%	2.21 [1.82, 2.68]	•
tal events	1304		1104				
idi injection(70-80ml ou,Y.2006	35	42	25	39	1.9%	2.80 [0.99, 7.94] 2	06
				27	0.4%	5.04 [0.53, 48,26] 2	108
ang,Q.2008	29 28	30 30	23 23	27 30	0.4%		1008
ng,Q.2008 ,D.2009	29 28	30 30	23 23	30	0.7%	4.26 [0.81, 22.53] 2	09
ang,Q.2008 r,D.2009 nang, L.2009	29	30	23			4.26 [0.81, 22.53] 2 1.88 [0.54, 6.54] 2	109
ng,Q.2008 ,D.2009	29 28 27	30 30 32	23 23 23	30 31	0.7% 1.6%	4.26 [0.81, 22.53] 20 1.88 [0.54, 6.54] 20 2.80 [1.01, 7.80] 20	109
ing,Q.2008 ,D.2009 iang, L.2009 ang,Y.2012	29 28 27 28	30 30 32 36	23 23 23 20	30 31 36	0.7% 1.6% 2.0%	4.26 [0.81, 22.53] 20 1.88 [0.54, 6.54] 20 2.80 [1.01, 7.80] 20 2.69 [0.63, 11.49] 20	009
ing,Q.2008 ,D.2009 lang, L.2009 ang,Y.2012 ,Y.2012	29 28 27 28 30	30 30 32 36 33	23 23 23 20 26	30 31 36 33	0.7% 1.6% 2.0% 1.1%	4.26 [0.81, 22.53] 20 1.88 [0.54, 6.54] 20 2.80 [1.01, 7.80] 20 2.69 [0.63, 11.49] 20	09
ng,Q.2008 ,D.2009 ang, L.2009 ang,Y.2012 ,Y.2012 en, Y.2016	29 28 27 28 30	30 30 32 36 33	23 23 23 20 26	30 31 36 33 30	0.7% 1.6% 2.0% 1.1% 1.6%	4.26 [0.81, 22.53] 2/ 1.88 [0.54, 6.54] 2/ 2.80 [1.01, 7.80] 2/ 2.69 [0.63, 11.49] 2/ 2.67 [0.84, 8.46] 2/	09
ng,Q.2008 D.2009 ang, L.2009 ang,Y.2012 Y.2012 ien, Y.2016 bibotal (95% CI) tal events terogeneity: Chi² = 0 st for overall effect: 2	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F	30 30 32 36 33 30 233	23 23 23 20 26 18 158 3); I² = 0%	30 31 36 33 30	0.7% 1.6% 2.0% 1.1% 1.6%	4.26 [0.81, 22.53] 2/ 1.88 [0.54, 6.54] 2/ 2.80 [1.01, 7.80] 2/ 2.69 [0.63, 11.49] 2/ 2.67 [0.84, 8.46] 2/	09
ng,Q.2008 D.2009 ang, L.2009 ang,Y.2012 Y.2012 en, Y.2016 btotal (95% CI) tal events terogeneity: Chi² = 0 st for overall effect: 2 di injection(90-100m	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F	30 30 32 36 33 30 233 6 (P = 0.99	23 23 23 20 26 18 158 9); ² = 0%	30 31 36 33 30 226	0.7% 1.6% 2.0% 1.1% 1.6% 9.3%	4.26 [0.81, 22.53] 2(1.88 [0.54, 6.54] 2(2.80 [1.01, 7.80] 2(2.69 [0.63, 11.49] 2(2.67 [0.84, 8.46] 2(2.80 [1.73, 4.52]	09
ng,Q.2008 D.2009 ang, L.2009 ang,Y.2012 Y.2012 en, Y.2016 btotal (95% CI) all events terogeneity: Chi² = 0 st for overall effect: 2 dl injection(90-100n n,G.2008	29 28 27 28 30 24 201 9.91, df = 6 Z = 4.20 (F	30 30 32 36 33 30 233 6 (P = 0.99 9 < 0.0001	23 23 23 20 26 18 158 9); 2 = 0%	30 31 36 33 30 226	0.7% 1.6% 2.0% 1.1% 1.6% 9.3%	4.26 [0.81, 22.53] 24 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52]	09 09 112 112 116
ng,Q.2008 D.2009 ng,Y.2019 ng,Y.2012 Y.2012 en,Y.2016 total (95% CI) al events rerogeneity: Chi ² = 0 tf for overall effect: 2 til injection(90-100m n,G.2008	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F	30 30 32 36 33 30 233 6 (P = 0.99 9 < 0.0001	23 23 23 20 26 18 158 3); ² = 0%	30 31 36 33 30 226	0.7% 1.6% 2.0% 1.1% 1.6% 9.3%	4.26 [0.81, 22.53] 24 1.88 [0.54, 6.54] 24 2.80 [1.01, 7.80] 24 2.69 [0.63, 11.49] 24 2.67 [0.84, 8.46] 24 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 24 1.61 [0.41, 6.30] 24	09 09 112 112 116
ng.Q.2008 D.2009 ng, L.2009 ng, Y.2012 Y.2012 y. 2016 total (95% CI) al events erogeneity: Chi² = 0 ts for overall effect: 2 ti injection(90-100m n.G.2008 Z.2011 Q.2011	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F	30 30 32 36 33 30 233 6 (P = 0.99 9 < 0.0001	23 23 23 20 26 18 158 9); I ² = 0%	30 31 36 33 30 226	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 21 2.69 [0.63, 11.49] 21 2.67 [0.84, 8.46] 21 2.80 [1.73, 4.52] 21 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 21 2.15 [0.36, 12.76] 21	09
ng,Q.2008 D.2009 p.ng, L.2009 ng, Y.2012 Y.2012 Y.2016 ototal (95% CI) al events errogeneity: Chi ² = 0 at for overall effect: 2 ii injection(90-100n n,G.2008 Z.2011 ng,S.2011	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F	30 30 32 36 33 30 233 6 (P = 0.99 9 < 0.0001	23 23 23 20 26 18 158 9); ² = 0%	30 31 36 33 30 226	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1%	4.26 [0.81, 22.53] 24 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2	009 009 112 112 116 111 111 111 111 111 111 111
ng.Q.2008 D.2009 ng, Y.2012 Y.2012 y.2012 en, Y.2016 btotal (95% CI) al events erogeneity: Chi ^p = 0 it for overall effect: 2 il injection(90-100n n.G.2008 Z.2011 ng.S.2011 ng.S.2011	29 28 27 28 30 32 24 201 9.91, df = 6 Z = 4.20 (F nl) 31 30 28 8 29 37	30 30 32 36 33 30 233 6 (P = 0.99 0 < 0.0001	23 23 23 20 26 18 158 3); ² = 0% 27 28 26 25 28	30 31 36 33 30 226 30 34 30 30 43	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 21 2.69 [0.63, 11.49] 21 2.67 [0.84, 8.46] 21 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 21 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 22 1.93 [0.42, 8.91] 23 3.30 [1.14, 9.60] 21	09
ng.Q.2008 D.2009 ng. L.2009 ng. Y.2012 Y.2012 Y.2016 total (95% CI) al events erogeneity: Chi² = 0 st for overall effect: 2 ii injection(90-100m n.G.2008 Z.2011 ng.S.2011 ng.S.2015 n, H.2015	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F ml) 31 30 28 29 37 19	30 30 32 36 33 30 233 5 (P = 0.99 5 < 0.0001 33 34 30 32 43 21	23 23 23 20 26 18 158 3); I ² = 0%	30 31 36 33 30 226 30 34 30 30 43 21	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.18% 0.6%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 21 2.69 [0.63, 11.49] 22 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 21 3.30 [1.14, 9.60] 21 4.75 [0.85, 26.43] 2	09
ng,Q.2008 D.2009 ng, L.2009 ng, Y.2012 Y.2012 Y.2016 botal (95% CI) al events erogeneity: Chi ² = 0 at for overall effect: 2 ii injection(90-100n n,G.2008 Z.2011 ng,S.2011 ng,S.2011 ng,S.2015 JC.2016	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F ml) 31 30 28 29 37 19 31	30 30 32 36 33 30 233 36 6 (P = 0.99 9 < 0.0001 33 34 30 32 43 21 35	23 23 23 20 26 18 158 3); ² = 0%	30 31 36 33 30 226 30 34 30 30 43 21 35	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 0.6% 1.3%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 1.89 [0.63, 11.49] 22 1.67 [0.84, 8.46] 22 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 1.51 [0.36, 12.76] 21 1.93 [0.42, 8.91] 2 1.75 [0.85, 26.43] 22 1.68 [0.74, 9.73] 2	009 009 112 112 116 116 116 116 116 116 116 116
ng.Q.2008 D.2009 ng, Y.2012 Y.2012 en, Y.2016 State (195% CI) al events erogeneity: Chi ² = 0 tt for overall effect: 2 til injection(90-100n n.G.2008 Z.2011 ng.S.2011 ng.S.2011 ng.S.2015 i, H.2015 Jc.2016 , T.2017	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F ml) 31 30 28 29 37 19	30 30 32 36 33 30 233 36 (P = 0.99 0 < 0.0001 33 34 30 32 43 21 35 67	23 23 23 20 26 18 158 3); I ² = 0%	30 31 36 33 30 226 30 34 30 30 43 21 35 68	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.8% 0.6% 1.3%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 22 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.67 [0.84, 8.46] 22 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 22 3.30 [1.14, 9.60] 24 7.5 [0.85, 26.43] 22 2.66 [0.74, 9.73] 22 2.66 [0.74, 9.73] 22 2.66 [0.78, 8.02] 24 2.66 [0.78, 8.02] 24 2.66 [0.88, 8.02] 24	09
ng,Q.2008 D.2009 D.2009 ng,Y.2012 Y.2012 Y.2016 btotal (95% CI) all events terogeneity: Chi² = 0 st for overall effect: 2 di injection(90-100m n.G.2008 Z.2011 ng,S.2011 ng,S.2015 n,H.2015 Jc.2016 JC.2017 btotal (95% CI)	29 28 27 28 30 24 201 0.91, df = 6 Z = 4.20 (F ml) 31 30 28 29 37 19 31	30 30 32 36 33 30 233 36 6 (P = 0.99 9 < 0.0001 33 34 30 32 43 21 35	23 23 23 20 26 18 158 3); ² = 0%	30 31 36 33 30 226 30 34 30 30 43 21 35	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 0.6% 1.3%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 1.89 [0.63, 11.49] 22 1.67 [0.84, 8.46] 22 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 1.51 [0.36, 12.76] 21 1.93 [0.42, 8.91] 2 1.75 [0.85, 26.43] 22 1.68 [0.74, 9.73] 2	009 009 112 112 116 116 116 116 116 116 116 116
ng,Q.2008 ,D.2009 ang, L.2009 ang,Y.2012 ,Y.2012 en, Y.2016 (btotal (95% CI) tal events terogeneity: Chi² = 0	29 28 27 28 30 24 20 1 20 1 30 28 29 37 19 31 62 267 1.51, df = 7	30 30 32 36 33 30 233 6 (P = 0.99 9 < 0.0001 33 34 30 32 43 21 35 67 295	23 23 23 20 26 18 158 3); I ² = 0%	30 31 36 33 30 226 30 34 30 30 43 21 35 68	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.8% 0.6% 1.3%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 22 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.67 [0.84, 8.46] 22 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 22 3.30 [1.14, 9.60] 24 7.5 [0.85, 26.43] 22 2.66 [0.74, 9.73] 22 2.66 [0.74, 9.73] 22 2.66 [0.78, 8.02] 24 2.66 [0.78, 8.02] 24 2.66 [0.88, 8.02] 24	009 009 112 112 116 116 116 116 116 116 116 116
ng,Q.2008 D.2009 ng,Y.2012 Y.2012 y.7.2012 en, Y.2016 btotal (95% CI) tal events terogeneity: Chi² = 0 st for overall effect: 2 di injection(90-100n n,G.2008 Z.2011 a,Q.2011 ng,S.2011 a,Q.2015 u, H.2015 Jc.2016 i, T.2017 btotal (95% CI) tal events terogeneity: Chi² = 1 st for overall effect: 2 di injection(others)	29 28 27 28 30 24 201 31 30 28 29 37 19 31 62 267 Z = 3.79 (F	30 30 32 36 33 30 233 5 (P = 0.98 5 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98	23 23 23 20 26 18 158 3); I ² = 0% 27 28 26 25 28 14 26 56 29 3); I ² = 0%	30 31 36 33 30 226 30 34 34 30 30 43 31 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.18% 0.6% 1.9% 9.7%	4.26 [0.81, 22.53] 2 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 2 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2 3.30 [1.14, 9.60] 2 4.75 [0.85, 26.43] 2 2.66 [0.74, 9.73] 2 2.66 [0.74, 9.73] 2 2.65 [0.88, 8.02] 2	09
ng.Q.2008 D.2009 ng.y.2012 y.2012 y.2012 y.2012 y.2016 total (95% CI) al events erogeneity: Chi² = 0 it for overall effect: 2 ii injection(90-100n n.G.2008 Z.2011 Q.2011 ng.S.2011 ng.S.2015 J. H.2015 Jc.2016 T.2017 total (95% CI) al events erogeneity: Chi² = 1 it for overall effect: 2 ii injection(others) ng.Y.2009	29 28 27 28 30 24 201	30 30 32 36 33 30 233 36 6 (P = 0.98 9 < 0.0001 33 34 30 32 43 35 6 (P = 0.98 9 < 0.0001	23 23 23 20 26 18 158 9); I² = 0% 158 27 28 26 25 28 14 26 56 56	30 31 36 33 30 226 30 34 30 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.15% 0.8% 1.13% 0.6% 1.3% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2 3.30 [1.14, 9.60] 2 4.75 [0.85, 26.43] 2 2.68 [0.74, 9.73] 2 2.66 [0.88, 8.02] 2 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 2	09
ng.Q.2008 D.2009 ng,Y.2012 Y.2012 en,Y.2016 btotal (95% CI) al events erogeneity: Chi ^p = 0 it for overall effect: 2 ii injection(90-100n n.G.2008 Z.2011 n.G.2011 ng.S.2015 i.H.2015 Jc.2016 ,T.2017 btotal (95% CI) al events erogeneity: Chi ^p = 1 it for overall effect: 2 ii injection(others) ng.Y.2009 2.2010	29 28 27 28 30 20 24 201 .51, df = 6 2 2 3.79 (f = 3.79	30 30 32 36 33 30 233 6 (P = 0.99 0 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 0 < 0.0001 32 33 34 35 36 37 38 38 39 30 30 30 30 30 30 30 30 30 30	23 23 23 20 26 18 158 3); ² = 0% 1 27 28 26 25 28 14 26 56 56 23 3); ² = 0%	30 31 36 33 30 226 30 34 30 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.8% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.67 [0.84, 8.46] 21 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 21 3.30 [1.14, 9.60] 24 4.75 [0.85, 26.43] 22 2.68 [0.74, 9.73] 22 2.66 [0.88, 8.02] 22 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 22 0.71 [0.28, 1.81] 21	009 009 112 112 116 116 117 117 117 117 117 117 117 117
Ig.Q.2008 D.2009 Ing. L.2009 Ing. L.2009 Ing. L.2019 Ing. L.2019 Ing. L.2019 Ing. L.2019 Ing. L.2016 I	29 28 27 28 30 24 201 0.91, df = 6 2 = 4.20 (f ml) 31 32 28 29 37 37 19 31 62 267 2 = 3.79 (f =	30 30 32 36 33 30 233 36 6 (P = 0.98 6 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 67 295	23 23 23 20 26 18 158 3); I ² = 0% 27 28 26 25 28 14 26 56 29 3); I ² = 0%	30 31 36 33 30 226 30 34 30 30 43 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 1.3% 1.9% 9.7%	4.26 [0.81, 22.53] 2 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 2 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2 3.30 [1.14, 9.60] 2 4.75 [0.85, 26.43] 2 2.66 [0.74, 9.73] 2 2.66 [0.88, 8.02] 2 2.55 [1.57, 4.14] 2 2.76 [0.62, 12.32] 2 0.71 [0.28, 1.81] 2 1.82 [0.36, 9.12] 2	09
Ig.Q.2008 D.2009 D.2009 Ing. L.2009 Ing. L.2009 Ing. L.2012 Y.2012 Y.2012 Ing. Y.2016 Ing. Y.2017 Ing. Y.2016 Ing. Y.2017 Ing. Y.2017 Ing. Y.2016 Ing.	29 28 27 28 30 24 201 31 30 28 29 37 19 31 62 25 3.79 (F	30 30 32 36 33 30 233 36 6 (P = 0.98 6 < 0.0001 33 34 30 32 43 35 6 (P = 0.98 7 (P = 0.98 6 = 0.0001 32 33 34 35 36 37 39 30 30 30 30 30 30 30 30 30 30	23 23 23 20 26 18 158 9); I² = 0% 1 27 28 26 25 28 14 26 25 28 14 26 56 56	30 31 36 33 30 226 30 34 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.8% 0.6% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2 3.30 [1.14, 9.60] 2 4.75 [0.85, 26.43] 2 2.68 [0.74, 9.73] 2 2.66 [0.88, 8.02] 2 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 2 0.71 [0.28, 1.81] 2 1.82 [0.36, 9.12] 2 0.93 [0.35, 2.47] 2 2.69 [0.35, 2.47] 2	09
ng.Q.2008 D.2009 ng.Y.2012 y.2012 y.2012 en, Y.2016 btotal (95% CI) al events erogeneity: Chi ² = 0 tt for overall effect: 2 til injection(90-100n n,G.2008 Z.2011 n,G.2011 ng.S.2015 n,H.2015 Jc.2016 Jc.2016 Jc.2016 jc.2017 total (95% CI) al events erogeneity: Chi ² = 1 tt for overall effect: 2 til injection(others) ng.Y.2009 L.2010 W.2011 W.2011 eng. B.2014 J.2016	29 28 27 28 30 20 24 201 0.91, df = 6 2 4.20 (f ml) 31 30 28 29 37 19 31 62 267 2.51, df = 7 2 = 3.79 (f 2 4.20 (f 3	30 30 32 36 33 30 233 86 (P = 0.98 9 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 9 < 0.0001 32 33 43 43 21 35 43 43 21 35 43 43 43 43 43 43 43 43 43 43	23 23 23 20 26 18 158 3); ² = 0% 27 28 26 25 28 14 26 56 25 28 14 26 56 25 28 14 26 3); ² = 0%	30 31 36 33 30 226 30 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.3% 1.9% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.67 [0.84, 8.46] 21 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 3.30 [1.14, 9.60] 24 4.75 [0.85, 26.43] 22 2.68 [0.74, 9.73] 22 6.66 [0.74, 9.73] 22 6.66 [0.74, 9.73] 22 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 22 0.71 [0.28, 1.81] 21 1.82 [0.36, 9.12] 21 0.83 [0.35, 2.47] 21 8.60 [1.82, 40.68] 27 2.86 [1.82, 40.68] 21	009 009 112 112 116 116 117 116 116 117 116 116 117 116 116
ng.Q.2008 D.2009 D.2009 ng.Y.2012 Y.2012 y.Y.2012 ng.Y.2016 St Groverall effect: 2 til injection(90-100n n.G.2008 T.2011 Q.2011 ng.S.2011 ng.S.2015 JC.2016 T.72017 Cototal (95% CI) al events ereogeneity: Chi² = 0 til injection(90-100n n.G.2008 T.2011 ng.S.2011 ng.S.2011 til injection(90-100n ng.S.2015 til injection(90-100n ng.S.2015 til injection(90-100n ng.Y.2019 T.2010 W.2011 ng.B.2014 J.2016 J.2010 W.2011 ng.B.2014 J.2016 J.2016 ng.H.2017	29 28 27 28 30 24 2011 30 28 29 31 28 29 31 5 2 2 267 1.51, df = 7 2 2 3.79 (f	30 30 32 36 33 30 233 36 6 (P = 0.98 6 < 0.0001 33 34 30 32 43 35 6 (P = 0.98 7 (P = 0.98 6 = 0.0001 32 33 34 35 36 37 39 30 30 30 30 30 30 30 30 30 30	23 23 23 20 26 18 158 3); I² = 0% 27 28 26 25 28 14 26 25 28 14 26 25 28 14 26 25 28 14 26 27 28 28 28 29 20 20 20 20 20 20 20 20 20 20 20 20 20	30 31 36 33 30 226 30 34 30 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 1.9% 4.7% 4.7% 4.7% 4.7% 0.6% 3.7% 0.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.69 [0.63, 11.49] 22 2.60 [1.73, 4.52] 22 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 23 2.68 [0.74, 9.73] 22 2.68 [0.74, 9.73] 22 2.68 [0.74, 9.73] 22 2.55 [1.57, 4.14] 22 2.76 [0.62, 12.32] 21 2.77 [0.28, 1.81] 21 2.78 [0.36, 9.12] 22 0.93 [0.35, 2.47] 28 8.60 [1.82, 40.69] 23 3.26 [0.63, 16.97] 24 3.26 [0.63, 16.97] 24 3.26 [0.63,	009 0112 112 112 116 008 1011 111 111 111 111 111 111 111 1
ng.Q.2008 D.2009 D.2009 ng.Y.2012 Y.2012 y.Y.2012 ng.Y.2016 St Groverall effect: 2 til injection(90-100n n.G.2008 T.2011 Q.2011 ng.S.2011 ng.S.2015 JC.2016 T.72017 Cototal (95% CI) al events ereogeneity: Chi² = 0 til injection(90-100n n.G.2008 T.2011 ng.S.2011 ng.S.2011 til injection(90-100n ng.S.2015 til injection(90-100n ng.S.2015 til injection(90-100n ng.Y.2019 T.2010 W.2011 ng.B.2014 J.2016 J.2010 W.2011 ng.B.2014 J.2016 J.2016 ng.H.2017	29 28 27 28 30 20 24 201 0.91, df = 6 2 4.20 (f ml) 31 30 28 29 37 19 31 62 267 2.51, df = 7 2 = 3.79 (f 2 4.20 (f 3	30 30 32 36 33 30 233 86 (P = 0.98 9 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 9 < 0.0001 32 33 43 43 21 35 43 43 21 35 43 43 43 43 43 43 43 43 43 43	23 23 23 20 26 18 158 3); ² = 0% 27 28 26 25 28 14 26 56 25 28 14 26 56 25 28 14 26 3); ² = 0%	30 31 36 33 30 226 30 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.3% 1.9% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2 3.30 [1.14, 9.60] 2 4.75 [0.85, 26.43] 2 2.68 [0.74, 9.73] 2 2.66 [0.88, 8.02] 2 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 2 0.71 [0.28, 1.81] 2 1.82 [0.36, 9.12] 2 0.93 [0.35, 2.47] 2 8.60 [1.82, 40.69] 2 3.26 [0.63, 16.97] 2 4.73 [0.94, 23.82] 2	009 012 112 112 116 108 101 111 111 115 115 116 117 119
ng.Q.2008 D.2009 D.2009 ang. L.2009 ang. L.2009 ang. L.2012 y.7.2012 en, Y.2012 en, Y.2016 btotal (95% CI) al events terogeneity: Chi² = 0 st for overall effect: 2 st injection(90-100n n.G.2001 ng.S.2011 ng.S.2011 ng.S.2011 ng.S.2015 n. H.2015 Jc.2016 n. T.2017 btotal (95% CI) al events terogeneity: Chi² = 1 st for overall effect: 2 st for overall effect: 2 st injection(others) ng.Y.2009 ng.Y.2009 L.2010 W.2011 eng. B.2014 J.2016 ang. H.2017 D.2019 enc.C.2020	29 28 27 28 30 24 2011 30 28 29 31 28 29 31 5 2 2 267 1.51, df = 7 2 2 3.79 (f	30 30 32 36 33 30 233 5 (P = 0.98 5 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 6 = 0.0001	23 23 23 20 26 18 158 3); I² = 0% 27 28 26 25 28 14 26 25 28 14 26 25 28 14 26 25 28 14 26 27 28 28 28 29 20 20 20 20 20 20 20 20 20 20 20 20 20	30 31 36 33 30 226 30 34 30 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 1.9% 4.7% 4.7% 4.7% 4.7% 0.6% 3.7% 0.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.69 [0.63, 11.49] 22 2.60 [1.73, 4.52] 22 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 23 2.68 [0.74, 9.73] 22 2.68 [0.74, 9.73] 22 2.68 [0.74, 9.73] 22 2.55 [1.57, 4.14] 22 2.76 [0.62, 12.32] 21 2.77 [0.28, 1.81] 21 2.78 [0.36, 9.12] 22 0.93 [0.35, 2.47] 28 8.60 [1.82, 40.69] 23 3.26 [0.63, 16.97] 24 3.26 [0.63, 16.97] 24 3.26 [0.63,	009 012 112 112 116 108 101 111 111 115 115 116 117 119
ng,Q.2008 D.2009 D.2009 ang,Y.2012 Y.,Y.2012 en,Y.2016 biotal (95% CI) tal events terogeneity: Chi² = 0 st for overall effect: 2 di injection(90-100n n,G.2008 Z.2011 a,Q.2011 ng,S.2015 u, H.2015 Jc.2016 Jc.2016 Jc.2016 st for overall effect: 2 di injection(others) ang,Y.2009 Z.2011 J. T.2017 biotal (95% CI) tal events terogeneity: Chi² = 1 st for overall effect: 2 di injection(others) ang,Y.2009 Z.2010 W.2011 eng, B.2014 J.2016 ang, H.2017 D.2019 enc,C.2020	29 28 27 28 30 24 201 31 30 28 29 37 19 31 62 26 39 37 Z = 3.79 (F	30 30 32 36 33 30 233 36 (P = 0.99 2 < 0.0001 33 34 30 32 43 35 6 (P = 0.99 2 < 0.0001 35 7 (P = 0.99 2 = 0.0001 32 36 39 49 47 52 41 41	23 23 23 20 26 18 158 9); I² = 0% 158 27 28 26 25 28 14 26 56 56 56 56 56 51 19 19 21 21 21 21 21 21 21 24 34 34 33 33	30 31 36 33 30 226 30 34 30 43 30 43 21 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.8% 0.6% 4.7% 1.9% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 2 2.80 [1.01, 7.80] 2 2.69 [0.63, 11.49] 2 2.67 [0.84, 8.46] 2 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 2 1.61 [0.41, 6.30] 2 2.15 [0.36, 12.76] 2 1.93 [0.42, 8.91] 2 3.30 [1.14, 9.60] 2 4.75 [0.85, 26.43] 2 2.68 [0.74, 9.73] 2 2.66 [0.88, 8.02] 2 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 2 0.71 [0.28, 1.81] 2 1.82 [0.36, 9.12] 2 0.93 [0.35, 2.47] 2 8.60 [1.82, 40.69] 2 3.26 [0.63, 16.97] 2 4.73 [0.94, 23.82] 2	009 112 112 112 114 115 115 116 117 119 119 120
ng, Q.2008 D.2009 ang, Y.2012 y.7.2012 en, Y.2016 btotal (95% CI) tal events terogeneity: Chi² = 0 st for overall effect: 2 ddi injection(90-100n n,G.2008 Z.2011 a,Q.2011 ng,S.2011 ao, S.2015 u, H.2015 Jc.2016 j. T.2016 j. T.2017 btotal (95% CI) tal events terogeneity: Chi² = 1	29 28 27 28 30 24 201 0.91, df = 6 2 4.20 (f ml) 31 30 28 29 37 19 31 62 267 2.51, df = 7 2 = 3.79 (f 2 3 9 45 50 39 44	30 30 32 36 33 30 233 8 (P = 0.98 9 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 9 = 0.0001 32 43 43 21 35 47 295 47 52 47 52 47 52 47 52 47 52 47 47 47 47 47 47 47 47 47 47	23 23 23 20 26 18 158 3); I² = 0% 27 28 26 25 28 14 26 56 25 28 14 26 56 27 28 14 26 27 28 14 26 33; I² = 0%	30 31 36 33 30 226 30 30 43 31 35 68 291	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.5% 0.8% 1.1% 1.3% 1.9% 9.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 22 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.67 [0.84, 8.46] 22 2.80 [1.73, 4.52] 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 22 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 21 3.30 [1.14, 9.60] 24 4.75 [0.85, 26.43] 22 2.68 [0.74, 9.73] 22 6.66 [0.74, 9.73] 22 6.66 [0.74, 9.73] 22 2.55 [1.57, 4.14] 2.76 [0.62, 12.32] 22 0.71 [0.28, 1.81] 21 1.82 [0.36, 9.12] 20 3.26 [0.63, 16.97] 24 4.73 [0.94, 23.82] 23 3.88 [1.28, 11.74] 23	009 112 112 112 114 115 115 116 117 119 119 120
ng,Q.2008 D.2009 nag, L.2009 nag, L.2009 nag, Y.2012 y., 2012 en, Y.2016 btotal (95% CI) tal events terogeneity: Chi² = 0 st for overall effect: 2 di injection(90-100n n.G.2008 Z.2011 ng,S.2011 ng,S.2011 ng,S.2015 n, H.2015 Jc.2016 n, T.2017 btotal (95% CI) tal events terogeneity: Chi² = 1 st for overall effect: 2 di injection(others) ing,Y.2009 Z.2010 w.2011 eng, B.2014 J.2019 eng, B.2014 J.2019 eng, C.2020 Z.2020 btotal (95% CI) tal events terogeneity: Chi² = 1	29 28 27 28 30 24 201 1.51, df = 6 29 37 79 (F	30 30 32 36 33 30 233 30 233 36 (P = 0.99 6 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 67 295 7 (P = 0.99 49 41 49 40 375 8 (P = 0.99 8 (P	23 23 23 20 26 18 158 3); I² = 0% 158 27 28 26 25 28 14 26 25 28 14 26 25 28 14 26 25 28 14 26 27 28 29 19 19 20 21 21 21 21 21 21 21 21 21 21 21 21 21	30 31 36 33 30 226 30 30 30 43 30 30 43 21 35 68 291 27 36 23 52 47 47 49 49 49	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 0.6% 6.1.3% 1.9% 9.7% 1.0% 4.7% 1.0% 0.7% 0.7% 0.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.69 [0.63, 11.49] 22 2.60 [1.73, 4.52] 22 2.80 [1.73, 4.52] 23 2.80 [1.73, 4.52] 24 2.80 [1.73, 4.52] 24 2.80 [1.73, 4.52] 24 2.80 [1.73, 4.52] 24 2.81 [1.73, 4.52] 25 2.82 [1.73, 4.52] 25 2.83 [1.74, 9.73] 22 2.85 [0.85, 26.43] 22 2.85 [1.87, 4.14] 22 2.76 [0.62, 12.32] 22 2.77 [0.28, 1.81] 21 2.78 [0.85, 2.47] 28 2.80 [1.82, 40.69] 23 2.86 [0.83, 16.97] 24 2.73 [0.94, 23.82] 23 3.88 [1.28, 11.74] 23 3.88 [1.28, 11.74] 23 3.84 [1.28, 11.74] 24 3.85 [1.28, 11.74] 24 3.85 [1.28, 11.74] 24 3.86 [1.28, 11	009 112 112 112 114 115 115 116 117 119 119 120
ng,Q.2008 D.2009 D.2009 ang, L.2009 ang, L.2009 ang, L.2012 y.7.2012 en, Y.2016 btotal (95% CI) al events terogeneity: Chi² = 0 st for overall effect: 2 st injection(90-100n n,G.2008 Z.2011 a.G.2011 ng,S.2011 a.G.2015 J. H.2015 JC.2016 J. T.2017 btotal (95% CI) al events terogeneity: Chi² = 1 st for overall effect: 2 st injection(others) ng,Y.2009 Z.2010 W.2011 eng, B.2014 J.2016 ang, H.2017 D.2019 en,C.2020 Z.2020 btotal (95% CI) al events terogeneity: Chi² = 1 al events en,C.2020 Z.2020 Lotal (95% CI) al events terogeneity: Chi² = 1	29 28 27 28 30 24 201 1.51, df = 6 29 37 79 (F	30 30 32 36 33 30 233 30 233 36 67 295 7 (P = 0.98 67 295 7 (P = 0.98 49 40 375 8 (P = 0.0001)	23 23 23 20 26 18 158 3); I² = 0% 158 27 28 26 25 28 14 26 25 28 14 26 25 28 14 26 25 28 14 26 27 28 29 19 19 20 21 21 21 21 21 21 21 21 21 21 21 21 21	30 31 36 33 30 226 30 34 30 30 43 35 68 291 27 36 23 52 47 72 41 49 40 367	0.7% 1.6% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 1.1% 1.9% 1.0% 3.7% 0.7% 1.0% 3.7% 0.7% 1.0% 1.9% 1.9%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 21 2.67 [0.84, 8.46] 21 2.80 [1.73, 4.52] 21 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 21 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 21 3.93 [1.14, 9.60] 24 1.75 [0.85, 26.43] 21 2.66 [0.88, 8.02] 21 2.55 [1.57, 4.14] 22 2.76 [0.62, 12.32] 21 0.71 [0.28, 1.81] 21 1.82 [0.36, 9.12] 21 0.93 [0.35, 2.47] 21 8.60 [1.82, 40.69] 21 3.88 [1.28, 40.69] 21 3.88 [1.28, 11.74] 23 1.81 [1.12, 8.82] 21 2.18 [1.48, 3.21]	009 112 112 112 114 115 115 116 117 119 119 120
ng,Q.2008 D.2009 D.2009 ang,Y.2012 Y.2012 Y.2016 btotal (95% CI) at events terogeneity: Chi² = 0 st for overall effect: 2 di injection(90-100n n,G.2008 Z.2011 n,G.2011 ng,S.2011 ao, S.2015 u, H.2015 Jc.2016 u, T.2017 btotal (95% CI) tal events terogeneity: Chi² = 1 st for overall effect: 2 di injection(others) ang,Y.2009 Z.2010 y.Y.2011 eng, B.2014 J.2016 ang,Y.2009 Z.2010 y.Y.2019 en,C.2020 Z.2010 btotal (95% CI) tal events terogeneity: Chi² = 1 st for overall effect: 2 di injection(others) ang,Y.2009 Z.2010 y.Z.2010 y.Z.2010 y.Z.2011 eng, B.2014 J.2016 ang, H.2017 J.2019 en,C.2020 Z.2020 btotal (95% CI) tal events terogeneity: Chi² = 1 st for overall effect: 2 tal (95% CI)	29 28 27 28 30 24 201 1.51, df = 6 29 37 19 31 62 29 37 19 31 52 267 2 = 3.79 (F 29 18 26 39 45 50 39 44 33 32 34.4.22, df = 7 2 = 3.92 (F	30 30 32 36 33 30 233 30 233 36 (P = 0.99 6 < 0.0001 33 34 30 32 43 21 35 67 295 7 (P = 0.98 67 295 7 (P = 0.99 49 41 49 40 375 8 (P = 0.99 8 (P	23 23 23 20 26 18 158 3); I² = 0% 158 26 25 28 14 26 25 28 14 26 25 28 14 26 27 28 29 29 20 21 21 21 21 21 21 21 21 21 21	30 31 36 33 30 226 30 34 30 30 43 35 68 291 27 36 23 52 47 72 41 49 40 367	0.7% 1.6% 2.0% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 0.6% 6.1.3% 1.9% 9.7% 1.0% 4.7% 1.0% 0.7% 0.7% 0.7%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 22 2.69 [0.63, 11.49] 22 2.60 [1.73, 4.52] 22 2.80 [1.73, 4.52] 23 2.80 [1.73, 4.52] 24 2.80 [1.73, 4.52] 24 2.80 [1.73, 4.52] 24 2.80 [1.73, 4.52] 24 2.81 [1.73, 4.52] 25 2.82 [1.73, 4.52] 25 2.83 [1.74, 9.73] 22 2.85 [0.85, 26.43] 22 2.85 [1.87, 4.14] 22 2.76 [0.62, 12.32] 22 2.77 [0.28, 1.81] 21 2.78 [0.85, 2.47] 28 2.80 [1.82, 40.69] 23 2.86 [0.83, 16.97] 24 2.73 [0.94, 23.82] 23 3.88 [1.28, 11.74] 23 3.88 [1.28, 11.74] 23 3.84 [1.28, 11.74] 24 3.85 [1.28, 11.74] 24 3.85 [1.28, 11.74] 24 3.86 [1.28, 11	009 112 112 112 114 115 115 116 117 119 119 120
ng,Q.2008 D.2009 D.2009 ang, L.2009 ang, L.2009 ang, L.2012 y.7.2012 en, Y.2016 btotal (95% CI) al events terogeneity: Chi² = 0 st for overall effect: 2 st injection(90-100n n,G.2008 Z.2011 a.G.2011 ng,S.2011 a.G.2015 J. H.2015 JC.2016 J. T.2017 btotal (95% CI) al events terogeneity: Chi² = 1 st for overall effect: 2 st injection(others) ng,Y.2009 Z.2010 W.2011 eng, B.2014 J.2016 ang, H.2017 D.2019 en,C.2020 Z.2020 btotal (95% CI) al events terogeneity: Chi² = 1 al events en,C.2020 Z.2020 Lotal (95% CI) al events terogeneity: Chi² = 1	29 28 27 28 30 20 24 2011 31 30 28 29 37 19 31 62 267 2.51, df = 7 Z = 3.79 (F Z = 3.92 (F	30 30 32 36 33 30 233 36 6 (P = 0.98 6 < 0.0001 33 43 21 35 67 295 7 (P = 0.98 67 295 7 (P = 0.98 7 (P = 0.98 8 (P = 0.0001 32 36 47 52 49 40 40 40 40 40 40 40 40 40 40	23 23 23 20 26 18 158 3); ² = 0% 158 26 25 28 14 26 56 25 28 14 26 56 21 21 19 42 34 46 33 34 46 24 27 48 28 29 20 21 21 21 21 21 21 21 21 21 21	30 31 36 33 30 226 30 34 30 30 43 35 68 291 27 36 23 52 47 72 41 49 40 367	0.7% 1.6% 1.1% 1.6% 9.3% 0.8% 1.1% 1.8% 1.1% 1.9% 1.0% 3.7% 0.7% 1.0% 3.7% 0.7% 1.0% 1.9% 1.9%	4.26 [0.81, 22.53] 21 1.88 [0.54, 6.54] 21 2.80 [1.01, 7.80] 22 2.69 [0.63, 11.49] 21 2.67 [0.84, 8.46] 21 2.80 [1.73, 4.52] 21 1.72 [0.27, 11.09] 21 1.61 [0.41, 6.30] 21 2.15 [0.36, 12.76] 21 1.93 [0.42, 8.91] 21 3.93 [1.14, 9.60] 24 1.75 [0.85, 26.43] 21 2.66 [0.88, 8.02] 21 2.55 [1.57, 4.14] 22 2.76 [0.62, 12.32] 21 0.71 [0.28, 1.81] 21 1.82 [0.36, 9.12] 21 0.93 [0.35, 2.47] 21 8.60 [1.82, 40.69] 21 3.88 [1.28, 40.69] 21 3.88 [1.28, 11.74] 23 1.81 [1.12, 8.82] 21 2.18 [1.48, 3.21]	009 112 112 112 114 115 115 116 117 119 119 120

Figure S69 Subgroups analysis of disease control rate by dosage of Aidi injection




Figure S70 Meta-regression of disease control rate by dosage of Aidi injection




Figure S71 Subgroups analysis of neutropenia by dosage of Aidi injection




Figure S72 Meta-regression of neutropenia by dosage of Aidi injection




Figure S73 Subgroups analysis of gastrointestinal reaction by dosage of Aidi injection




Figure S74 Meta-regression of gastrointestinal reaction by dosage of Aidi injection




Figure S75 Subgroups analysis of objective response rate by treatment time




Figure S76 Meta-regression of objective response rate by treatment time




Figure S77 Subgroups analysis of disease control rate by treatment time




Figure S78 Meta-regression of disease control rate by treatment time




Figure S79 Subgroups analysis of neutropenia by treatment time




Figure S80 Meta-regression of neutropenia by treatment time




Figure S81 Subgroups analysis of gastrointestinal reaction by treatment time




Figure S82 Meta-regression of gastrointestinal reaction by treatment time




Figure S83 Subgroups analysis of objective response rate by treatment cycle




Figure S84 Meta-regression of objective response rate by treatment cycle




Figure S85 Subgroups analysis of disease control rate by treatment cycles




Figure S86 Meta-regression of disease control rate by treatment cycle




Figure S87 Subgroups analysis of neutropenia by treatment cycle




Figure S88 Meta-regression of neutropenia by treatment cycle




Figure S89 Subgroups analysis of gastrointestinal reaction by treatment cycle




Figure S90 Meta-regression of gastrointestinal reaction by treatment cycle

9	Events	ction Total	Gemcitabine and of Events		Weight	Odds Ratio M-H, Fixed, 95% C	l Year	M-H, Fixed, 95% CI
splatin (20-30mg/m ²)	42	13	20	1.4%	2.67 [1.08, 6.58]	2000	
ou,Y.2006	24	33	15	39 30	1.4%			
ın,G.2008	17 17	32	12	27	1.4%	1.06 [0.40, 2.86]		
ang,Y.2009						1.42 [0.51, 3.96]		
ong,Z.2009	10	30	9	30	1.4%	1.17 [0.39, 3.47]		
ı,Y.2010	16	32	10	32	1.2%	2.20 [0.79, 6.10]		
Z.2010	16	36	12	36	1.6%	1.60 [0.62, 4.16]		
i,X.2010	13	28	10	28	1.3%	1.56 [0.53, 4.56]		
ong,Y.2010	57	90	32	70	3.1%	2.05 [1.09, 3.88]		
ou,A.2010	16	40	14	38	2.0%	1.14 [0.46, 2.85]	2010	
u,Q.2011	17	30	11	30	1.1%	2.26 [0.80, 6.36]		
n,S.2011	22	41	12	38	1.4%	2.51 [1.00, 6.29]	2011	
ang,Y. 2012	21	41	15	42	1.7%	1.89 [0.78, 4.55]	2012	
ang,J.2012	14	25	10	24	1.1%	1.78 [0.57, 5.53]	2012	
i, W.2012	15	40	11	40	1.6%	1.58 [0.62, 4.07]	2012	
, L.2012	19	35	16	35	1.7%	1.41 [0.55, 3.61]		-
n,J.2012	15	34	13	34	1.7%	1.28 [0.48, 3.36]		
i,L.2013	45	70	40	70	3.4%	1.35 [0.68, 2.67]		
, H.2013	19	38	18	42	2.0%	1.33 [0.55, 3.22]		
		49						
neng, B.2014	12		16	52	2.8%	0.73 [0.30, 1.76]		
u, H.2015	15	21	7	21	0.5%	5.00 [1.35, 18.55]	2015	
ao, S.2015	19	43	12	43	1.6%	2.05 [0.83, 5.02]		
ang, M.2015	17	39	12	32	1.8%	1.29 [0.50, 3.35]		
ang, S.2016	11	19	8	19	0.8%	1.89 [0.52, 6.85]		
nen, Y.2016	15	30	13	30	1.5%	1.31 [0.47, 3.61]	2016	
a, Y. 2016	19	33	19	35	1.9%	1.14 [0.44, 2.98]	2016	
J.2016	23	47	9	47	1.1%	4.05 [1.61, 10.20]	2016	
u, T.2017	53	67	40	68	2.0%	2.65 [1.24, 5.68]		
ang, H.2017	42	52	26	52	1.2%	4.20 [1.75, 10.11]		
ang, W.2017	17	39	11	40	1.5%	2.04 [0.80, 5.21]		+
, S.2017	35	40	23	39	0.7%	4.87 [1.57, 15.13]		
ou, D.2018	30	58	22	58	2.5%	1.75 [0.84, 3.67]		
, W.2018	16	30	15	30	1.7%	1.14 [0.41, 3.15]		
, vv.2016 J, H.2019	19	44	12	44	1.6%			
i, H.2019 ien,C.2020	26	49	16	49	1.8%	2.03 [0.83, 4.95] 2.33 [1.03, 5.29]		
eng,K.2020	27	45	17	45	1.6%	2.47 [1.06, 5.77]		
n, H.2020	24	60	18	60	2.6%	1.56 [0.73, 3.31]		
, Y.2020	16	45	12	45	1.8%	1.52 [0.62, 3.73]		·
,Z.2020	25	40	14	40	1.2%	3.10 [1.24, 7.71]	2020	
ıbtotal (95% CI)		1567		1534	62.9%	1.83 [1.58, 2.12]		▼
2	,	< 0.000	101)					
est for overall effect: Z splatin (40-50mg/m² ng,P.2011 ang Y.2012	²) 9	18	10	22 36	1.1%	1.20 [0.34, 4.18] 1.26 [0.49, 3.21]		
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012	9 16	18 36	10 14	36	1.8%	1.26 [0.49, 3.21]	2012	
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013	9 16 19	18 36 34	10 14 12	36 34	1.8% 1.3%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16]	2012 2013	
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014	9 16 19 16	18 36 34 30	10 14 12 12	36 34 30	1.8% 1.3% 1.3%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77]	2012 2013 2014	
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014	9 16 19 16 28	18 36 34 30 45	10 14 12 12 17	36 34 30 45	1.8% 1.3% 1.3% 1.5%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36]	2012 2013 2014 2014	
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014 J,Y.2014	9 16 19 16 28 18	18 36 34 30 45 43	10 14 12 12 17 17	36 34 30 45 43	1.8% 1.3% 1.3% 1.5% 2.3%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60]	2012 2013 2014 2014 2014	
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014 J,Y.2014	9 16 19 16 28	18 36 34 30 45 43	10 14 12 12 17	36 34 30 45 43 41	1.8% 1.3% 1.3% 1.5% 2.3% 1.1%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75]	2012 2013 2014 2014	
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014 J,Y.2014	9 16 19 16 28 18	18 36 34 30 45 43	10 14 12 12 17 17	36 34 30 45 43	1.8% 1.3% 1.3% 1.5% 2.3%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60]	2012 2013 2014 2014 2014	•
splatin (40-50mg/m ²) ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014 J.Y.2014 J.D.2019 ibtotal (95% CI) tal events oterogeneity: Chi ² = 5. st for overall effect: Z	9 16 19 16 28 18 30 136 .90, df = 6	18 36 34 30 45 43 41 247 (P = 0.4	10 14 12 12 17 17 17 17 99	36 34 30 45 43 41	1.8% 1.3% 1.3% 1.5% 2.3% 1.1%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75]	2012 2013 2014 2014 2014	•
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014 J.P.2014 J.P.2019 jubtotal (95% CI) tital events tel events tel events stel or overall effect: Z	9 16 19 16 28 18 30 136 .90, df = 6 5 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.4	10 14 12 12 17 17 17 17 17 99 13); ² = 0%	36 34 30 45 43 41 251	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.6] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69]	2012 2013 2014 2014 2014 2019	•
splatin (40-50mg/m ² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 en, H.2014 ,Y.2014 ,D.2019 lbtotal (95% CI) tal events betrogeneity: Chi ² = 5. st for overall effect: Z	9 16 19 16 28 18 30 136 -90, df = 6 2 = 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.4	10 14 12 12 17 17 17 17 17 17 19 99	36 34 30 45 43 41 251	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69]	2012 2013 2014 2014 2014 2019	•
splatin (40-50mg/m ² g.p.2011 ang. Y.2012 S. S. 2013 H. 2014 an, H. 2014 d. T. 2019 btotal (95% CI) tall events terogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² ao.H. 2008 an. G. 2008	9 16 19 16 28 18 30 136 90, df = 6 = 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.4	10 14 12 12 17 17 17 17 17 19 99 99 13); I ² = 0%	36 34 30 45 43 41 251	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98]	2012 2013 2014 2014 2019 2019	•
splatin (40-50mg/m ²) rg.P.2011 rg.P.2012 s.2013 H.2014 rg.P.2014 rg.P.2014 rg.P.2014 rg.P.2014 rg.P.2019 biotal (95% CI) tal events tetrogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² rg.P.2008 rg.X.2008	9 16 19 16 28 18 30 136 .90, df = 6 2 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.44 = 0.000 30 68	10 14 12 12 17 17 17 17 17 19 99 13); ² = 0%	36 34 30 45 43 41 251	1.8% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35]	2012 2013 2014 2014 2019 2019 2008 2008 2008	•
splatin (40-50mg/m ² rg.P.2011 ang,Y.2012 S.2013 H.2014 an, H.2014 ry.Y.2014 D.2019 btotal (95% CI) tal events terogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² ao,H.2008 rg,X.2008 an,K.2009	16 19 16 28 18 30 136 .90, df = 6 = 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.40 30 30 68 38	10 14 12 12 17 17 17 17 17 17 17 5)	36 34 30 45 43 41 251	1.8% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79]	2012 2013 2014 2014 2019 2008 2008 2008 2009	•
splatin (40-50mg/m ² rg.P.2011 ang,Y.2012 S.2013 H.2014 an, H.2014 ry.Y.2014 D.2019 btotal (95% CI) tal events terogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² ao,H.2008 rg,X.2008 an,K.2009	9 16 19 16 28 18 30 136 .90, df = 6 2 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.40 30 30 30 68 38 30	10 14 12 12 17 17 17 17 17 19 99 13); ² = 0%	36 34 30 45 43 41 251 20 27 62 38 30	1.8% 1.3% 1.3% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79]	2012 2013 2014 2014 2019 2008 2008 2008 2009 2009	•
splatin (40-50mg/m ² g.p.?.2011 ang. Y.2012 S. S. 2013 H. 2014 an, H. 2014 h. Y. 2014 [95% CI) tatl events the rogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² ao, H. 2008 ng. X. 2008 ng. X. 2008 ng. X. 2009 D. 2009 [D. 2009	16 19 16 28 18 30 136 .90, df = 6 = 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.40 30 30 68 38	10 14 12 12 17 17 17 17 17 17 17 5)	36 34 30 45 43 41 251	1.8% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79]	2012 2013 2014 2014 2019 2008 2008 2008 2009 2009	•
splatin (40-50mg/m ²) rg.P.2011 ang.Y.2012 S.2013 H.2014 rg.Y.2014 rg.Y.2014 rg.Y.2014 rg.Y.2014 rg.Y.2019 biotal (95% CI) tal events tetrogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² rg.Q.2008 rg.X.2008 rg.X.2008 rg.X.2009 ang.L.2009 ang.L.2009 ang.L.2009	9 16 19 16 28 18 30 136 .90, df = 6 2 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.40 30 30 30 68 38 30	10 14 12 12 17 17 17 17 17 19 99 13); I ² = 0%	36 34 30 45 43 41 251 20 27 62 38 30	1.8% 1.3% 1.3% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.00 [0.47, 2.69] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89]	2012 2013 2014 2014 2019 2008 2008 2008 2009 2009 2009	•
splatin (40-50mg/m ² g.p.?.2011 ang.Y.2012 S.2013 H.2014 an, H.2014 J. 2019 bitotal (95% CI) tal events terogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² ap.H.2008 ng.X.2008 ng.X.2008 ng.X.2009 ng.X.2009 ng.S.2011	136 19 16 28 18 30 136 90, df = 6 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.4 = 0.000 30 68 38 30 32	10 14 12 12 17 17 17 17 17 99 99 13); ² = 0%	36 34 30 45 43 41 251 20 27 62 38 30 31	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79]	2012 2013 2014 2014 2019 2008 2008 2008 2009 2009 2011	→
splatin (40-50mg/m ² g.p.?.2011 ang. Y.2012 S. S. 2013 H. 2014 an. H. 2014 an. H. 2014 d.p. 2019 bitotal (95% CI) tal events the rogeneity: Chi ² = 5. st for overall effect: Z splatin (60-80mg/m ² ao.H. 2008 ng. X. 2008 an. K. 2009 D. 2009 ang. L. 2009 ang. L. 2009 ing. Z. 2011 j. Z. 2011	136 28 30 136 22 155 18	18 36 34 30 45 43 41 247 (P = 0.4 2 = 0.000 30 68 38 30 32 32 34	10 14 12 12 17 17 17 17 17 99 83); ² = 0%	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.6% 1.9%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.45] 1.07 [0.40, 2.89] 1.32 [0.48, 3.63] 1.33 [0.43, 2.91]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2009 2011 2011	•
splatin (40-50mg/m² g,P.2011 ang,Y.2012 S.2013 H.2014 an, H.2014 g,Y.2014 [0,2019 biotal (95% Ci) tal events tetrogeneity: Chi² = 5, st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ng,X.2008 ng,X.2008 an,K.2009 D,2009 ang, L.2009 ng,S.2011 Z.2011	9 16 19 16 28 18 30 136 90, df = 6 2 3.48 (F 23 30 16 22 15 15 18 15	18 36 34 30 45 43 41 247 (P = 0.000 30 30 38 38 30 32 32 34 29	10 14 12 12 17 17 17 17 17 99 13); ² = 0% 6 11 25 15 11 14 12 17	36 34 30 45 43 41 251 20 27 62 38 30 31 30 31 30 32 32	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.6% 1.9%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.69] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.32 [0.48, 3.63] 1.31 [0.43, 2.91] 1.39 [0.46, 4.18]	2012 2013 2014 2014 2019 2008 2008 2008 2009 2009 2011 2011	•
splatin (40-50mg/m ² g,P.2011 ang,Y.2012 S. S.2013 H.2014 an, H.2014 h, V.2014 J. Color bit of the color bi	9 16 19 16 28 18 18 30 136 5 5 15 11	18 36 34 30 45 43 41 247 (P = 0.000 30 30 68 38 30 32 32 34 42 27 7	10 14 12 12 17 17 17 17 17 99 99 13); I² = 0% 6 11 25 15 11 14 12 17 10 10	36 34 30 45 43 41 251 20 27 62 38 30 31 31 30 34 23 27	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.6% 1.9% 1.9%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.37 [0.40, 4.8] 1.13 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2011	
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 an, H.2014 J.Y.2014 J.P.2019 bibtotal (95% CI) tat events berogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2.008 ang,X.2008 ang,X.2008 ang,X.2009 ang,L.2009 ang,L.2009 ang,L.2009 ang,L.2011 J.Z.2011 J.Z.2011 J.Z.2011	9 16 19 16 28 18 30 136 29 14 6 6 2 18 30 16 16 17 18 18 18 15 11 19	18 36 34 30 45 43 41 247 (P = 0.000 30 30 32 32 34 29 27 31	10 14 12 12 17 17 17 17 17 99 83); ² = 0% 6 11 25 15 11 14 12 17 10 10	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34 23 27 31	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.6% 1.9% 1.3% 1.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 1.39 [0.40, 4.81] 1.31 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2015	•
splatin (40-50mg/m² ng.P.2011 ang.Y.2012 S.2013 H.2014 n, H.2014 ,V.2014 ,V.2014 ,V.2014 j.D.2019 bitotal (95% CI) tal events teterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao.H.2008 ang.X.2008 ang.X.2008 ang.X.2009 ang.X.2009 ang.X.2011 J.2011 J.2011 J.2011 J.2011 J.2015 Jc.2016	9 16 19 16 28 18 30 136 5 5 15 15 11 19 21	18 36 34 30 45 43 41 247 (P = 0.0000 30 30 30 32 32 32 34 29 27 31 35	10 14 12 12 17 17 17 17 17 99 13); ² = 0% 6 11 25 15 11 14 12 17 10 10 11 15	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34 43 27 31 31	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 1.8% 1.6% 1.3% 1.4% 1.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.69] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.32 [0.48, 3.63] 1.13 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18]	2012 2013 2014 2014 2019 2008 2008 2008 2009 2009 2011 2011 2011 2014 2015 2016	
splatin (40-50mg/m² g.p./2011 ang. Y.2012 S. S. 2013 H. 2014 an, H. 2014 h. Y. 2014 (D. 2019 btotal (95% CI) tal events terogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao.H. 2008 ng. X. 2008 ng. X. 2008 ng. X. 2008 ng. X. 2009 ng. X. 2011 X. 2011 J. 2011 J. 2011 J. 2011 J. 2016 ng. L. 2016	9 16 19 16 28 30 136 90, df = 6 = 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.000 30 30 68 38 30 32 32 34 42 27 31 35 45 45	10 14 12 12 17 17 17 17 17 19 99 61 11 25 15 11 14 12 17 10 10 11 11 12 17 17 17	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34 23 27 31 355 45	1.8% 1.3% 1.5% 2.3% 10.4% 10.4% 10.4% 1.1% 0.6% 2.1% 0.7% 1.8% 1.9% 1.9% 1.4% 1.0% 1.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.39 [0.46, 4.8] 1.39 [0.46, 4.18] 1.41 [0.43, 2.91] 1.39 [0.46, 4.18] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87]	2012 2013 2014 2014 2019 2019 2008 2008 2009 2009 2011 2011 2011 2015 2016 2016	• • • • • • • • • • • • • • • • • • •
splatin (40-50mg/m² g,P.2011 ang,Y.2012 S. S.2013 H.2014 an, H.2014 in,Y.2014 J. D.2019 bitotal (95% CI) tal events terogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ang,X.2008 ang,X.2008 ang,X.2009 ang,L.2009 ang,L.2009 ang,L.2009 ang,L.2011 J.2011 J.2014 J.S.2015 Jc.2016 ang, X.2016 ang, X.2016	9 16 19 16 28 18 30 136 .90, df = 6 2 3.48 (F	18 36 34 30 45 43 34 1247 (P = 0.0000 30 30 30 32 32 34 29 27 7 31 35 45 25	10 14 12 12 17 17 17 17 17 99 8) 6 11 25 15 11 14 12 17 10 10 11 15 27 8	36 34 30 45 43 41 251 251 20 27 62 38 30 31 30 34 23 27 31 35 45 25	1.8% 1.3% 1.5% 2.3% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.9% 1.3% 1.4% 1.4% 1.4% 1.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 1.39 [0.40, 4.8] 1.31 [0.40, 2.89] 1.32 [0.48, 3.63] 1.33 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2015 2016 2016	•
splatin (40-50mg/m ² g.p.?.2011 ang. Y.2012 s. S.2013 H.2014 an, H.2014 h. H.2014 h. H.2014 h. D.2019 bitotal (95% CI) tall events terogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m ² ao.H.2008 ang. X.2008 ang. X.2008 ang. X.2009 ng. S.2011 J.2014 g. S.2015 Jc.2016 ang. L.2016 ang. M.2017	9 16 28 18 130 136 90, df = 6 2 3.48 (F 1) 11 23 30 16 22 15 18 15 11 19 19 19 19 19 19 19 19 19 19 19 19	18 36 34 30 45 43 41 247 (P = 0.0000 68 38 30 32 23 44 29 27 35 45 45 42 42	10 14 12 12 17 17 17 17 17 99 99 13); ² = 0% 6 11 25 15 11 14 12 17 10 10 11 11 15 27 8	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34 32 27 31 35 45 25 45 45	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 10.4% 1.1% 0.6% 2.1% 0.7% 1.8% 1.6% 1.9% 1.4% 1.4% 1.4% 1.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.81] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2016 2016 2016 2016 2016	
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 an, H.2014 h,P.2014 h,P.2014 h,P.2019 bibtotal (95% CI) tat events sterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ng,X.2008 ang,X.2008 ang,X.2009 h,P.2009 h,P.2009 ang, L.2011 h,P.2011 J,P.2011 h,P.2011 J,P.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2017 ao,J,2019	9 16 19 16 28 18 30 136 .90, df = 6 2 3.48 (F	18 36 34 30 45 43 1 247 (P = 0.000 30 30 32 34 429 27 31 35 45 25 42 43 43	10 14 12 12 17 17 17 17 17 99 8) 6 11 25 15 11 14 12 17 10 10 11 15 27 8	36 34 30 45 43 41 251 251 20 27 62 38 30 31 30 34 23 27 31 35 45 42 43 43	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.6% 1.3% 1.9% 1.3% 1.4% 0.5% 1.4% 0.5%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.32 [0.48, 3.63] 1.31 [0.43, 2.91] 1.39 [0.46, 4.18] 1.47 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2016 2016 2016 2016 2016	•
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 ,S.2013 H.2014 an, H.2014 J.Y.2014 J.P.2019 bitotal (95% CI) tal events sterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ang,X.2008 ang,X.2008 ang,X.2009 ang, L.2009 ang, L.2009 ang, L.2009 ang, L.2011 J.W.2011 J.J.2014 J.S.2015 Jc.2016 ang, X.2016 ang, X.2016 ang, X.2019 bitotal (95% CI)	9 16 19 16 28 18 30 136 6 6 5 3.48 (F	18 36 34 30 45 43 41 247 (P = 0.0000 68 38 30 32 23 44 29 27 35 45 45 42 42	10 14 12 12 17 17 17 17 17 99 99 13); I ² = 0% 6 11 25 15 11 14 12 17 10 10 11 15 27 8 12 22	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34 32 27 31 35 45 25 45 45	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 10.4% 1.1% 0.6% 2.1% 0.7% 1.8% 1.6% 1.9% 1.4% 1.4% 1.4% 1.4%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.81] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2016 2016 2016 2016 2016	•
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 an, H.2014 h,P.2014 h,P.2014 h,P.2014 h,P.2019 bibtotal (95% CI) tata events oterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ng,X.2008 ng,X.2008 ng,X.2009 h,P.2009 h,P.2001 h,P.2016 h,P	9 16 19 16 28 18 18 30 136 90, df = 6 23 30 15 15 15 15 18 15 18 19 21 31 319 8.63, df =	18 36 34 30 45 43 41 247 (P = 0.000 68 38 30 32 32 32 44 29 27 31 35 45 45 45 45 45 45 15 (P =	10 14 12 12 17 17 17 17 17 17 19 99 11 25 15 11 14 12 17 10 10 11 15 27 8 12 27 8 12 22 22 226 0.34); I² = 10%	36 34 30 45 43 41 251 251 20 27 62 38 30 31 30 34 23 27 31 35 45 42 43 43	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.6% 1.3% 1.9% 1.3% 1.4% 0.5% 1.4% 0.5%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.32 [0.48, 3.63] 1.31 [0.43, 2.91] 1.39 [0.46, 4.18] 1.47 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2016 2016 2016 2016 2016	•
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 en, H.2014 J. V.2014 d.D.2019 elbtotal (95% CI) tatal events beterogeneity: Chi² = 5, st for overall effect: Z splatin (60-80mg/m² ang, L.2008 ang, L.2009 ang, L.2009 ang, L.2009 ang, L.2011 J.2011 d.Z.2011 d.Z.2011 d.Z.2016 ang, L.2016 ang, L.2016 ang, L.2016 ang, L.2016 ang, L.2017 ata.J.2019 and L.2019 and L.2019 and L.2019 and L.2016 ang, L.2016 ang, L.2016 ang, L.2016 ang, L.2016 and L.2019 and L.	9 16 19 16 28 18 18 30 136 90, df = 6 23 30 15 15 15 15 18 15 18 19 21 31 319 8.63, df =	18 36 34 30 45 43 41 247 (P = 0.000 68 38 30 32 32 32 44 29 27 31 35 45 45 45 45 45 45 15 (P =	10 14 12 12 17 17 17 17 17 17 19 99 11 25 15 11 14 12 17 10 10 11 15 27 8 12 27 8 12 22 22 226 0.34); I² = 10%	36 34 30 45 43 41 251 251 20 27 62 38 30 31 30 34 23 27 31 35 45 42 43 43	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.6% 1.3% 1.9% 1.3% 1.4% 0.5% 1.4% 0.5%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.32 [0.48, 3.63] 1.31 [0.43, 2.91] 1.39 [0.46, 4.18] 1.47 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04]	2012 2013 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2016 2016 2016 2016 2016	•
splatin (40-50mg/m² ng.P.2011 ang.Y.2012 s.S.2013 H.2014 en, H.2014 J.Y.2014 j.Y.2014 j.Y.2014 j.Y.2014 j.Y.2014 j.Y.2014 j.Y.2014 j.Y.2014 j.Y.2015 eterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² lao,H.2008 en,K.2009 en,K.2009 en,K.2009 ang.S.2011 j.Z.2011 j.Y.2011 j.Y.2011 j.Y.2014 eng. S.2015 j.C.2016 eng. X.2016 ang. X.2016 ang. X.2016 j. j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2011 j.Y.2015 eng. X.2016 j. j.Y.2016 eng. X.2016 j. j.Y.2017 j.Y.2019 j.Y	9 16 19 16 28 18 18 30 136	18 36 34 30 45 43 41 247 (P = 0.000 68 38 30 32 32 32 44 29 27 31 35 45 45 45 45 45 45 45 45 45 45 45 45 45	10 14 12 12 17 17 17 17 17 17 19 99 11 25 15 11 14 12 17 10 10 11 15 27 8 12 27 8 12 22 22 226 0.34); I ² = 10%	36 34 30 45 43 41 251 20 27 62 38 30 31 30 34 23 27 31 35 42 43 35 43 44 41 41 41 41 41 41 41 41 41 41 41 41	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.9% 1.3% 1.4% 1.0% 1.4% 1.6% 1.6% 2.3.2%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.35] 1.12 [0.45, 2.35] 1.31 [0.40, 2.89] 1.32 [0.48, 3.63] 1.31 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2019 2008 2008 2009 2011 2011 2011 2016 2016 2017 2019	•
splatin (40-50mg/m² ng.P.2011 ang.Y.2012 s.S.2013 H.2014 en, H.2014 h.D.2019 bibtoal (95% CI) tatal events teterogeneity: Chi² = 5. tst for overall effect: Z splatin (60-80mg/m² ng.V.2008 en,K.2009 ng.Q.2008 ang.X.2008 en,K.2009 ng.S.2011 J.2014 ng.S.2015 J.C.2016 ang. L.2016 ang. X.2016 ang. X.2016 ang. X.2016 ang. X.2016 ang. X.2016 ang. X.2016 ang. X.2019 bibtoal (95% CI) tatal events teterogeneity: Chi² = 16 tst for overall effect: Z splatin (others) x.Y.2012	9 16 28 30 136 29, df = 6 23 3.48 (F 22 15 18 19 31 319 6.63, df = 6 4.89 (F 16 16 16 16 16 16 16 16 16 16 16 16 16	18 36 34 30 45 54 31 41 247 (P = 0.000 30 30 30 30 30 30 30 30 30 30 30 30	10 14 12 12 17 17 17 17 17 19 99 99 13); ² = 0% 6 11 25 15 11 14 12 17 10 10 11 11 15 27 8 12 22 22 22 23 24 25 26 27 27 27 28 29 20 20 20 20 20 20 20 20 20 20	36 34 30 45 43 41 251 20 27 62 38 30 31 30 31 35 45 542 43 543	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.3% 1.4% 1.4% 1.4% 1.5% 23.2%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.8] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 1.83] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	•
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 en, H.2014 J.P.2014 i.D.2019 ibtotal (95% CI) tatal events sterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao.H.2008 nng,X.2008 en,K.2009 j.D.2009 ang,L.2009 ang,L.2011 j.Z.2011 j.Z.2011 j.Z.2011 j.Z.2011 j.Z.2016 nng, X.2016 ang,X.2016 ang,X.2016 ang,L.2016 sharg,X.2016 sharp,X.2016 sharp,X.2017 sharp,X.2018 sharp,	9 16 19 16 28 18 18 30 136	18 36 34 30 45 43 41 247 (P = 0.000 30 30 30 30 32 32 34 429 27 31 35 45 42 43 571 15 (P = < 0.000 33 33 36 33 36 33 36 36	10 14 12 12 17 17 17 17 17 17 19 99 11 25 15 11 14 12 17 10 10 11 15 27 8 12 27 8 12 22 22 226 0.34); I ² = 10%	36 34 30 45 43 41 251 251 20 27 62 38 30 31 30 34 23 25 45 42 43 543 543 36 6	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 10.4% 1.1% 1.6% 1.6% 1.9% 1.3% 1.4% 1.0% 1.4% 1.5% 23.2%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.42, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.39 [0.46, 4.18] 1.13 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 an, H.2014 J.Y.2014 J.Y.2014 J.P.2019 bibtotal (95% CI) tat events berogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ang,X.2008 ang,X.2008 ang,X.2009 ang, L.2009 ang, L.2009 ang, L.2009 ang, L.2011 J.Z.2011 J.Z.2011 J.Z.2011 J.Z.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 sh,M.2017 ao,J.2019 bibtotal (95% CI) tat events terorgeneity: Chi² = 16 st for overall effect: Z splatin (others) J.Y.2012 in, R.2015 bibtotal (95% CI)	9 16 19 16 28 18 30 136 .90, df = 6 := 3.48 (F 1) 11 23 30 16 16 17 18 19 21 18 18 19 21 18 18 19 21 18 18 19 21 18 18 18 18 18 18 18 18 18 18 18 18 18	18 36 34 30 45 54 31 41 247 (P = 0.000 30 30 30 30 30 30 30 30 30 30 30 30	10 14 12 12 17 17 17 17 17 17 19 99 13); I ² = 0% 6 11 25 15 11 14 12 17 10 10 11 15 27 8 12 22 22 22 26 0.34); I ² = 10% 101)	36 34 30 45 43 41 251 20 27 62 38 30 31 30 31 35 45 542 43 543	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 10.4% 1.1% 0.6% 3.5% 2.1% 0.7% 1.8% 1.3% 1.4% 1.4% 1.4% 1.5% 23.2%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.78 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.8] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 1.83] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 en, H.2014 h,P.2014 (5.2014 en, H.2014 en, H.2016 en, H.2016 en, H.2016 en, H.2016 en, H.2016 en, H.2016 en, K.2009 en, K.2009 en, K.2009 en, K.2011 en, K.2011 en, K.2011 en, K.2016 en, H.2016 en,	9 16 19 16 28 18 18 30 136 90, df = 6 6 22 15 18 15 15 18 18 15 18 18 15 18 18 15 18 18 18 18 18 18 18 18 18 18 18 18 18	18 36 34 30 45 43 41 247 (P = 0.000 30 30 30 30 30 32 32 44 39 25 42 43 571 15 (P = < 0.000 30 66 69 (P = 0.4 50 69 40 69 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 6	10 14 12 12 17 17 17 17 17 19 99 13); I ² = 0% 6 11 25 15 11 14 12 17 10 10 11 15 27 8 12 22 22 0.34); I ² = 10% 101)	36 34 30 45 43 41 251 251 20 27 62 38 30 31 30 34 23 25 45 42 43 543 543 36 6	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 10.4% 1.1% 1.6% 1.6% 1.9% 1.3% 1.4% 1.0% 1.4% 1.5% 23.2%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.42, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.39 [0.46, 4.18] 1.13 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 an, H.2014 h,P.2014 h,P.2014 and P.2019 hibtotal (95% CI) tatal events terogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ang,H.2008 ng,K.2008 ng,K.2008 ng,K.2009 h,P.2011 b,P.2011 b,P.2011 b,P.2011 b,P.2011 b,P.2016 ang,K.2016 and better sterogeneity: Chi² = 16 st for overall effect: Z splatin (others) st for overall effect: Z	9 16 19 16 28 18 18 30 136 90, df = 6 6 22 15 18 15 15 18 18 15 18 18 15 18 18 15 18 18 18 18 18 18 18 18 18 18 18 18 18	18 36 34 30 45 43 41 247 (P = 0.000 30 30 30 30 30 32 32 44 39 25 42 43 571 15 (P = < 0.000 30 66 69 (P = 0.4 50 69 40 69 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 40 69 6	10 14 12 12 17 17 17 17 17 19 99 13); I ² = 0% 6 11 25 15 11 14 12 17 10 10 11 15 27 8 12 22 22 0.34); I ² = 10% 101)	36 34 30 45 43 41 251 251 20 27 62 38 83 33 34 23 27 31 355 25 42 43 543 36 69	1.8% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 10.4% 1.1% 1.6% 1.6% 1.9% 1.3% 1.4% 1.0% 1.4% 1.5% 23.2%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	
splatin (40-50mg/m² ng,P.2011 ang,Y.2012 s,S.2013 H.2014 n, H.2014 h,Y.2014 b,Y.2014 b,Y.2014 b,Y.2014 condition (95% CI) tata events sterogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ao,H.2008 ng,X.2008 ng,X.2008 ng,X.2009 ng,X.2009 ng,X.2011 J.2011 J.2011 J.2011 J.2011 J.2011 J.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 ang,X.2016 sh,Y.2017 ao,J.2017 ao,J.2017 ao,J.2019 tist events terogeneity: Chi² = 16 st for overall effect: Z splatin (others) y.Y.2012 nn, R.2015 bitotal (95% CI) tatal events teterogeneity: Chi² = 10 st for overall effect: Z splatin (others) y.Y.2012 nn, R.2015 bitotal (95% CI) tatal events teterogeneity: Chi² = 0. st for overall effect: Z	9 16 19 16 28 18 18 30 136 90, df = 6 = 3.48 (F 12 30 16 16 17 17 18 18 15 18 15 18 15 18 15 18 19 21 17 18 18 19 21 17 18 18 19 21 17 18 18 19 21 17 18 18 19 21 17 18 18 19 21 17 18 18 19 21 18 18 19 21 18 18 19 21 18 18 19 21 18 18 19 21 18 18 19 21 18 18 19 21 18 18 19 21 18 18 18 19 21 18 18 18 19 21 18 18 18 19 21 18 18 18 18 18 18 18 18 18 18 18 18 18	18 36 34 30 45 5 42 43 30 30 32 33 44 29 92 77 31 15 (P = 1 < 0.000 33 66 86 69 69 69 9 0.48)	10 14 12 12 17 17 17 17 17 19 99 61 11 25 15 11 14 12 17 10 10 11 15 27 8 12 27 8 12 22 22 22 0.34); I ² = 10% 101)	36 34 30 45 43 41 251 251 20 27 62 38 83 33 34 23 27 31 355 25 42 43 543 36 69	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 10.4% 1.1% 10.5% 1.6% 1.9% 1.3% 1.4% 1.0% 2.1% 1.5% 2.1% 1.4% 2.1% 1.4% 2.1%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.42, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.39 [0.46, 4.18] 1.13 [0.43, 2.91] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	
splatin (40-50mg/m² 19,P.2011 ang,Y.2012 s. S.2013 H.2014 an, H.2014 an, H.2014 [95% CI) tat events terogeneity: Chi² = 5. st for overall effect: Z splatin (60-80mg/m² ang,X.2008 ang,X.2008 ang,X.2008 ang,X.2009 [0.2009 ang, L.2011 ang,S.2015 [0.2014] [0.2014] [0.2014] [0.2014] [0.2016] [0.	9 16 18 30 136 22 155 18 19 31 319 6.63, df = 1 4 30 .51, df = 1 1319	18 36 34 30 45 43 41 247 (P = 0.000 30 30 30 30 30 30 30 30 30 30 30 30	10 14 12 12 17 17 17 17 17 17 19 99 99 13); ² = 0% 6 11 25 15 11 14 12 17 10 10 11 11 15 27 8 12 22 22 22 23 24 25 16 17 17 10 10 11 11 11 12 13 14 15 16 17 18 19 10 10 10 10 10 10 10 10 10 10	36 34 30 45 43 41 251 251 20 27 62 38 83 33 34 23 27 31 355 25 42 43 543 36 69	1.8% 1.3% 1.3% 1.5% 2.3% 1.1% 10.4% 1.1% 10.4% 1.1% 10.5% 1.6% 1.9% 1.3% 1.4% 1.0% 2.1% 1.5% 2.1% 1.4% 2.1% 1.4% 2.1%	1.26 [0.49, 3.21] 2.32 [0.87, 6.16] 1.71 [0.62, 4.77] 2.71 [1.16, 6.36] 1.10 [0.47, 2.60] 3.85 [1.52, 9.75] 1.88 [1.32, 2.69] 1.35 [0.40, 4.53] 4.76 [1.52, 14.98] 1.17 [0.58, 2.35] 1.12 [0.45, 2.79] 4.75 [1.58, 14.25] 1.07 [0.40, 2.89] 1.39 [0.46, 4.18] 1.17 [0.39, 3.49] 2.88 [1.03, 8.07] 2.00 [0.77, 5.18] 2.33 [0.93, 5.87] 5.46 [1.63, 18.36] 2.07 [0.84, 5.10] 2.47 [1.01, 6.04] 1.83 [1.43, 2.32]	2012 2013 2014 2014 2014 2019 2008 2008 2009 2009 2011 2011 2014 2016 2016 2017 2019	0.01 0.1 10

Figure S91 Subgroups analysis of objective response rate by cisplatin dosage




Figure S92 Meta-regression of objective response rate by cisplatin dosage

2	Aidi injed	Total	Gemcitabine and Events		Weight	Odds Ratio M-H, Fixed, 95% CI Ye	Odds Ratio ar <u>M-H. Fixed, 95% Cl</u>
i splatin (20-30mg/m²) ou,Y.2006) 35	42	25	39	1.9%	2.80 [0.99, 7.94] 20	06
un,G.2008	31	33	27	30	0.8%	1.72 [0.27, 11.09] 20	
ong,Z.2009	27	30	25	30	1.1%	1.80 [0.39, 8.32] 20	
ang,Y.2009	29	32	21	27	1.0%	2.76 [0.62, 12.32] 20	
ong,Y.2010	78	90	50	70	3.4%	2.60 [1.17, 5.78] 20	10
ou,A.2010	37	40	29	38	1.0%	3.83 [0.95, 15.43] 20	
hi,X.2010	27	28	25	28	0.4%	3.24 [0.32, 33.22] 20	
i,Z.2010	18	36	21	36	4.7%	0.71 [0.28, 1.81] 20	
iu,Y.2010	25	32	22	32	2.2%	1.62 [0.53, 4.99] 20	
an,S.2011 /u,Q.2011	35 28	41 30	29 26	38 30	2.0% 0.8%	1.81 [0.58, 5.68] 20 2.15 [0.36, 12.76] 20	
u, L.2012	32	35	28	35	1.1%	2.67 [0.63, 11.31] 20	
un,J.2012	25	34	25	34	3.0%	1.00 [0.34, 2.94] 20	
/ang,J.2012	20	25	16	24	1.5%	2.00 [0.55, 7.31] 20	
ei, W.2012	35	40	27	40	1.5%	3.37 [1.07, 10.61] 20	
hang,Y. 2012	34	41	32	42	2.4%	1.52 [0.52, 4.47] 20	
u, H.2013	33	38	34	42	1.9%	1.55 [0.46, 5.24] 20	13
ai,L.2013	63	70	60	70	2.7%	1.50 [0.54, 4.20] 20	13
heng, B.2014	39	49	42	52	3.7%	0.93 [0.35, 2.47] 20	14
hu, H.2015	19	21	14	21	0.6%	4.75 [0.85, 26.43] 20	
hang, M.2015	28	39	23	32	3.2%	1.00 [0.35, 2.82] 20	
hao, S.2015	37	43	28	43	1.8%	3.30 [1.14, 9.60] 20	
hen, Y.2016	24	30	18	30	1.6%	2.67 [0.84, 8.46] 20	
i, J.2016	45	47	34	47	0.7%	8.60 [1.82, 40.69] 20	
hang, S.2016	14	19	14	19	1.7%	1.00 [0.24, 4.24] 20	
la, Y. 2016	28	33	28	35	1.9%	1.40 [0.40, 4.94] 20	
u, S.2017	37	40	26	39	0.9%	6.17 [1.60, 23.83] 20	
hang, H.2017	50 36	52	46 30	52	0.8%	3.26 [0.63, 16.97] 20	
luang, W.2017 Vu, T.2017	36 62	39 67	30 56	40 68	1.0% 1.9%	4.00 [1.01, 15.87] 20 2.66 [0.88, 8.02] 20	
vu, 1.2017 v, W.2018	24	30	25	30	1.9% 2.2%	0.80 [0.22, 2.97] 20	
v, w.2018 hou, D.2018	50	58	25 38	58	2.2%	3.29 [1.31, 8.27] 20	
iu, H.2019	39	44	30	44	1.5%	3.64 [1.18, 11.23] 20	
an, H.2020	49	60	39	60	3.2%	2.40 [1.03, 5.57] 20	
u, Y.2020	43	45	33	45	0.7%	7.82 [1.64, 37.36] 20	
u,Z.2020	33	40	24	40	1.9%	3.14 [1.12, 8.82] 20	
hen,C.2020	44	49	34	49	1.6%	3.88 [1.28, 11.74] 20	
eng,K.2020	39	45	31	45	1.9%	2.94 [1.01, 8.53] 20	
ubtotal (95% CI)		1567		1534	68.3%	2.26 [1.87, 2.72]	◆
otal events	1352		1135				
i splatin (40-50mg/m²) Vang,Y.2012) 28	36	20	36	2.0%	2.80 [1.01, 7.80] 20	12
u,S.2013	32	34	29	34	0.8%	2.76 [0.50, 15.33] 20	13
i, H.2014	26	30	23	30	1.4%	1.98 [0.51, 7.63] 20	14
iu,Y.2014	35	43	33	43	2.8%	1.33 [0.47, 3.77] 20	
Ven, H.2014	43	45	36	45	0.7%	5.38 [1.09, 26.49] 20	
u,D.2019	39	41 229	33	41	0.7%	4.73 [0.94, 23.82] 20	19
				229	8.4%	2.56 [1.52, 4.31]	
ubtotal (95% CI) otal events	203	223	174				
otal events leterogeneity: Chi² = 3. lest for overall effect: Z	.09, df = 5 = 3.54 (P	(P = 0.6	9); I ² = 0%				
otal events leterogeneity: Chi² = 3.	.09, df = 5 = 3.54 (P	(P = 0.6	9); I ² = 0%	62	2.3%	1.11 [0.34, 3.63] 20	08
otal events leterogeneity: Chi² = 3. est for overall effect: Z sisplatin (60-80mg/m²)	.09, df = 5 = 3.54 (P	(P = 0.6 = 0.000	9); I ² = 0% 4)	62 27	2.3% 0.4%	1.11 [0.34, 3.63] 20 5.04 [0.53, 48.26] 20	
otal events leterogeneity: Chi² = 3. est for overall effect: Z isplatin (60-80mg/m² eng,X.2008	09, df = 5 = 3.54 (P) 62	(P = 0.6 = 0.000	9); I ² = 0% 4)				08
otal events eterogeneity: Chi² = 3. est for overall effect: Z isplatin (60-80mg/m² eng,X.2008 ang,Q.2008 v,D.2009	09, df = 5 = 3.54 (P) 62 29	(P = 0.6 = 0.000	9); I ² = 0% 4) 56 23	27	0.4%	5.04 [0.53, 48.26] 20	08
otal events leterogeneity: Chi² = 3. lest for overall effect: Z lisplatin (60-80mg/m² eng,X.2008	09, df = 5 = 3.54 (P) 62 29 28	(P = 0.6 = 0.000 68 30 30	9); I ² = 0% 4) 56 23 23	27 30	0.4% 0.7%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20	008
otal events eterogeneity: Chi² = 3. est for overall effect: Z isplatin (60-80mg/m²) eng,X.2008 ang,Q.2008 v,D.2009 /en,K.2009 hang, L.2009	09, df = 5 = 3.54 (P) 62 29 28 32 27 26	(P = 0.6 = 0.000 68 30 30 38 32 29	9); I ² = 0% 4) 56 23 23 32 23 19	27 30 38 31 23	0.4% 0.7% 2.3% 1.6% 1.0%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20	08
otal events leterogeneity: Chi² = 3. est for overall effect: Z lisplatin (60-80mg/m² eng.X.2008 ang.Q.2008 v.D.2009 len.X.2009 le.W.2009 le.W.2011	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30	(P = 0.6 = 0.000- 68 30 30 38 32 29 34	9); I ² = 0% 4) 56 23 23 32 23 19 28	27 30 38 31 23 34	0.4% 0.7% 2.3% 1.6%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20	08
otal events leterogeneity: Chi² = 3. est for overall effect: Z cisplatin (60-80mg/m² eng,X.2008 eng,X.2008 vp. D.2009 ven,K.2009	09, df = 5 = 3.54 (P) 62 29 28 32 27 26	(P = 0.6 = 0.000 68 30 30 38 32 29	9); I ² = 0% 4) 56 23 23 32 23 19	27 30 38 31 23	0.4% 0.7% 2.3% 1.6% 1.0%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20	08
otal events leterogeneity: Chi ² = 3. sest for overall effect: Z sest for overall effect: Z eng.X.2008 ang.Q.2008 v.D.2009 l/en,K.2009 l/en,K.2009 l/en,K.2011 lang.S.2011 lang.S.2011 lang.S.2011 l.J.2014	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19	(P = 0.6 = 0.000 68 30 30 38 32 29 34 32 27	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16	27 30 38 31 23 34 30 27	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.81 [0.41, 6.30] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20	08
otal events leterogeneity: Chi² = 3. set for overall effect: Z sisplatin (60-80mg/m² eng.X.2008 eng.X.2009 ven.K.2009 len.K.2009 len.X.2001 lew.Z.2011 u.Z.2011 iang.S.2011 i.J.2014 ing. S.2015	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26	(P = 0.66 = 0.0000	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16	27 30 38 31 23 34 30 27 31	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.61 [0.41, 6.30] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20	08
otal events eterogeneity: Chi² = 3. est for overall effect: Z isplatin (60-80mg/m²) eng, X.2008 eng, X.2009 (vn. X.2009 hang, L.2009 e, W. 2011 u, Z.2011 ang, S.2011 i, J.2014 ing, S.2015 i, Jc.2016	09, df = 5 = 3.54 (P)) 62 29 28 32 27 26 30 29 19 26 31	(P = 0.60 a) 68 30 30 38 32 29 34 32 27 31 35	9); I ² = 0% 4) 56 23 23 23 32 23 19 28 25 16 22 26	27 30 38 31 23 34 30 27 31 35	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6%	5.04 [0.53, 48.26] 2C 4.26 [0.81, 22.53] 2C 1.00 [0.29, 3.43] 2C 1.88 [0.54, 6.54] 2C 1.82 [0.36, 9.12] 2C 1.61 [0.41, 6.30] 2C 1.93 [0.42, 8.91] 2C 1.63 [0.53, 5.04] 2C 2.13 [0.62, 7.29] 2C 2.68 [0.74, 9.73] 2C	08
otal events leterogeneity: Chi² = 3. sest for overall effect: Z sest for overall effect: Z eng.X.2008 eng.X.2008 v. D.2009 eng.X.2009 eng.X.2009 eng.X.2009 eng.X.2009 lew.X.2011 u.Z.2011 u.Z.2011 i.J.2014 ii.J.2014 ii.J.2016 hang.X.2016 hang.X.2016 hang.X.2016 hang.X.2016	09, df = 5 = 3.54 (P)) 62 29 28 32 27 26 30 29 19 26 31 21	(P = 0.60 = 0.000 d = 0.00	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26	27 30 38 31 23 34 30 27 31 35 25	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.3%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.61 [0.41, 6.30] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 2 4.13 [1.09, 15.59] 20	08
otal events leterogeneity: Chi² = 3. set for overall effect: Z sisplatin (60-80mg/m²), eng. X.2008 eng. X.2009 eng. X.2009 len, X.2009 len, X.2011 u.Z.2011 ing. S. 2011 i. J. 2014 ling. S. 2015 i. Jc. 2016 hang. L. 2016 ang. L. 2016 ang. L. 2016	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42	(P = 0.6 = 0.000-0	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26 14 34	27 30 38 31 23 34 30 27 31 35 25	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.3% 1.0%	5.04 [0.53, 48.26] 2C 4.26 [0.81, 22.53] 2C 1.00 [0.29, 3.43] 2C 1.88 [0.54, 6.54] 2C 1.82 [0.36, 9.12] 2C 1.61 [0.41, 6.30] 2C 1.93 [0.42, 8.91] 2C 1.63 [0.52, 7.29] 2C 2.68 [0.74, 9.73] 2C 4.13 [1.09, 15.59] 2C 4.53 [1.17, 17.55] 2C	08
otal events leterogeneity: Chi² = 3. sest for overall effect: Z sisplatin (60-80mg/m²); chiplatin (60-	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37	(P = 0.6 = 0.000 d = 0.000	9); I ² = 0% 4) 56 23 23 23 32 23 19 28 25 16 22 26 14 34 29	27 30 38 31 23 34 30 27 31 35 25 45	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0%	5.04 [0.53, 48.26] 2C 4.26 [0.81, 22.53] 2C 1.00 [0.29, 3.43] 2C 1.88 [0.54, 6.54] 2C 1.82 [0.36, 9.12] 2C 1.61 [0.41, 6.30] 2C 1.93 [0.42, 8.91] 2C 1.63 [0.52, 5.04] 2C 2.13 [0.62, 7.29] 2C 2.68 [0.74, 9.73] 2C 4.13 [1.09, 15.59] 2C 4.53 [1.17, 17.55] 2C 3.32 [1.06, 10.37] 2C	08
otal events leterogeneity: Chi² = 3. sest for overall effect: Z sest for overall effect fo	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42	(P = 0.6 = 0.000-0000000000000000000000000000000	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26 14 34	27 30 38 31 23 34 30 27 31 35 25 45 42	0.4% 0.7% 2.3% 1.6% 1.0% 1.1% 2.1% 1.6% 1.3% 1.0% 1.0% 1.6%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.42, 8.91] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.73] 20 2.58 [0.73, 9.14] 20	08
otal events leterogeneity: Chi² = 3. set for overall effect: Z sisplatin (60-80mg/m²), eng. X.2008 eng. X.2008 eng. X.2009 len, X.2009 len, X.2011 u.Z.2011 ing. S. 2011 i. J. 2014 ling. S. 2015 i. Jc. 2016 hang. L. 2016 land, X.2016 land, L. 2016 land, L. 2016 land, L. 2017 land, L. 2017 land, L. 2017 land, L. 2018 land, L. 2016 land, L. 2017 land, L. 2019 ubtotal (95% CI)	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37 39	(P = 0.6 = 0.000 d = 0.000	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26 14 34 29 34	27 30 38 31 23 34 30 27 31 35 25 45	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0%	5.04 [0.53, 48.26] 2C 4.26 [0.81, 22.53] 2C 1.00 [0.29, 3.43] 2C 1.88 [0.54, 6.54] 2C 1.82 [0.36, 9.12] 2C 1.61 [0.41, 6.30] 2C 1.93 [0.42, 8.91] 2C 1.63 [0.52, 5.04] 2C 2.13 [0.62, 7.29] 2C 2.68 [0.74, 9.73] 2C 4.13 [1.09, 15.59] 2C 4.53 [1.17, 17.55] 2C 3.32 [1.06, 10.37] 2C	08
otal events eterogeneity: Chi² = 3. est for overall effect: Z isplatin (60-80mg/m² eng.X.2008 y.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2009 v.D.2001 i.J.2.2011 i.J.2.2011 i.J.2.2011 i.J.2.2015 j.J.2.2016 ang. L.2016 ang. L.2016 ang. L.2016 ang. L.2016 ang. L.2016 ang. L.2017 b.J.2.2017 b.J.2.2019 ubtotal vents eterogeneity: Chi² = 7.	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37 39 478 21, df = 1/2	(P = 0.6 = 0.000 de 8 de 30 de 30 de 38 de 32 de	9); I ² = 0% 4) 56 23 23 32 23 32 25 16 22 26 14 34 29 34	27 30 38 31 23 34 30 27 31 35 25 45 42	0.4% 0.7% 2.3% 1.6% 1.0% 1.1% 2.1% 1.6% 1.3% 1.0% 1.0% 1.6%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.42, 8.91] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.73] 20 2.58 [0.73, 9.14] 20	08
otal events leterogeneity: Chi² = 3. est for overall effect: Z est for overall effect: Z eng.X.2008 eng.X.2009 eng.X.2009 eng.X.2009 eng.X.2009 lew.X.2011 elw.X.2011 elw.X.2011 elw.X.2011 elw.X.2014 ling.S.2015 els.JC.2016 eng.X.2016 eng.X.	09, df = 5 = 3.54 (P) 62	(P = 0.6 = 0.000 de 8 de 30 de 30 de 38 de 32 de	9); I ² = 0% 4) 56 23 23 32 23 32 25 16 22 26 14 34 29 34	27 30 38 31 23 34 30 27 31 35 25 45 42	0.4% 0.7% 2.3% 1.6% 1.0% 1.1% 2.1% 1.6% 1.3% 1.0% 1.0% 1.6%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.42, 8.91] 20 1.93 [0.42, 8.91] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.13 [1.09, 15.59] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 1.037] 20 2.58 [0.73, 9.14] 20 2.25 [0.73, 9.14] 20	08
otal events leterogeneity: Chi² = 3. sest for overall effect: Z sisplatin (60-80mg/m²); chiplatin (60-	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37 39 478 21, df = 1/2	(P = 0.6 = 0.000 de 8 de 30 de 30 de 38 de 32 de	9); I ² = 0% 4) 56 23 23 32 23 32 25 16 22 26 14 34 29 34	27 30 38 31 23 34 30 27 31 35 25 45 42	0.4% 0.7% 2.3% 1.6% 1.0% 1.1% 2.1% 1.6% 1.3% 1.0% 1.0% 1.6%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.42, 8.91] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.73] 20 2.58 [0.73, 9.14] 20	08
otal events leterogeneity: Chi² = 3. est for overall effect: Z eng,X.2008 ang,Q.2008 v,D.2009 ven,K.2009 lew,X.2011 u,Z.2011 u,Z.2011 u,Z.2011 u,J.2014 li,J.e.2016 li,J.e.201	09, df = 5 = 3.54 (P) 62	(P = 0.6 68 30 30 32 29 34 32 27 31 35 45 42 42 45 41 4 (P = 0.000)	9); I ² = 0% 4) 56 23 23 32 23 32 25 16 22 26 14 34 29 34 404 93); I ² = 0% 01)	27 30 38 31 23 34 30 27 31 35 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0% 1.0% 20.9%	5.04 [0.53, 48.26] 26 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.36, 9.12] 20 1.83 [0.35, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 2.55 [0.73, 9.14] 2 2.25 [1.61, 3.15] 2.69 [0.63, 11.49] 20 2.67 [0.74, 9.63] 20	08
otal events leterogeneity: Chi² = 3. sest for overall effect: Z sisplatin (60-80mg/m²); eng. X.2008 eng. X.2009 eng. X.2009 eng. X.2009 eng. X.2011 eng. X.2011 eng. X.2011 eng. X.2011 eng. X.2011 eng. X.2016 en	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37 39 47 48 21, df = 1 = 4.72 (P	(P = 0.6 68 30 30 30 38 32 29 34 43 22 27 31 4 45 42 43 44 4 (P = 0.000)	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26 14 34 29 34 404 93); I ² = 0% 01)	27 30 38 31 23 34 30 27 31 35 25 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0% 1.0%	5.04 [0.53, 48.26] 20 4.26 [0.81, 22.53] 20 1.08 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.63 [0.41, 6.30] 20 1.93 [0.42, 8.91] 20 1.63 [0.52, 7.29] 20 2.68 [0.74, 9.73] 20 4.13 [1.09, 15.59] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 2.58 [0.73, 9.14] 20 2.25 [1.61, 3.15]	08
otal events leterogeneity: Chi² = 3. sest for overall effect: Z sest for overall effect: Z eng.X.2008 ang.Q.2008 v.D.2009 len.K.2009 len.K.2009 len.K.2009 len.K.2011 lang.S.2011 lang.S.2011 lang.S.2016 hang. L.2016 hang. X.2016 lang. L.2016 lang. L.2016 lang. L.2016 lang. S.2015 lang. S.2016 lang. L.2016 lang. L.2016 lang. L.2016 lang. L.2016 lang. S.2015 lang. S.201	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37 39 478 21, df = 1 = 4.72 (P	(P = 0.6 68 30 30 30 32 29 34 32 277 31 35 25 45 42 43 36 44 (P = 0.000)	9); I ² = 0% 4) 56 23 23 23 32 23 19 28 25 16 22 26 14 34 29 34 404 93); I ² = 0%	27 30 38 31 23 34 30 27 31 35 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0% 1.0% 20.9%	5.04 [0.53, 48.26] 26 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.36, 9.12] 20 1.83 [0.35, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 2.55 [0.73, 9.14] 2 2.25 [1.61, 3.15] 2.69 [0.63, 11.49] 20 2.67 [0.74, 9.63] 20	08
otal events leterogeneity: Chi² = 3. est for overall effect: Z eng,X.2008 ang,Q.2008 v,D.2009 ven,K.2009 lew,X.2011 u,Z.2011 u,Z.2011 u,Z.2011 u,J.2014 li,J.e.2016 li,J.e.201	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 41 42 37 39 478 21, df = 1/2 = 4.72 (P	(P = 0.6 68 30 30 30 38 32 29 34 32 27 31 35 45 42 43 3544 (P = 0.000 69 69 (P = 0.9 0.000 69 10 0.000	9); I ² = 0% 4) 56 23 23 23 32 23 19 28 25 16 22 26 14 34 29 34 404 93); I ² = 0%	27 30 38 31 23 34 30 27 31 35 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0% 1.0% 20.9%	5.04 [0.53, 48.26] 26 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.36, 9.12] 20 1.83 [0.35, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 2.55 [0.73, 9.14] 2 2.25 [1.61, 3.15] 2.69 [0.63, 11.49] 20 2.67 [0.74, 9.63] 20	08
otal events leterogeneity: Chi² = 3. lest for overall effect: Z	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 41 42 37 39 478 21, df = 1/2 = 4.72 (P	(P = 0.6, 69 (P = 0.00)	9); I ² = 0% 4) 56 23 23 23 32 23 19 28 25 16 22 26 14 34 29 34 404 93); I ² = 0%	27 30 38 31 23 34 30 27 31 35 25 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.1% 2.1% 1.6% 1.3% 1.0% 1.6% 1.4% 20.9%	5.04 [0.53, 48.26] 26 4.26 [0.81, 22.53] 20 1.08 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.61 [0.41, 6.30] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20 2.13 [0.62, 7.29] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 4.53 [1.17, 17.55] 20 3.22 [1.66, 10.37] 20 2.58 [0.73, 9.14] 20 2.25 [1.61, 3.15] 2.69 [0.63, 11.49] 20 2.67 [0.74, 9.63] 20 2.68 [1.02, 7.01]	08
otal events eterogeneity: Chi² = 3. est for overall effect: Z eng.X.2008 y.X.2008 y.V.2009 y.V.2009 y.V.2009 y.V.2009 y.V.2009 y.V.2009 y.V.2011 y.Z.2011 y.Z.2011 y.Z.2011 y.Z.2011 y.Z.2016 hang. X.2016 hang. X.2016 hang. X.2016 hang. X.2016 hang. X.2016 hang. X.2016 y.J.2016 hang. X.2016 hang. X.2016 hang. X.2016 hang. X.2017 hao,J.2019 ubtotal (95% CI) otal events eterogeneity: Chi² = 7. est for overall effect: Z isplatin (others) y.Y.2012 an, R.2015 ubtotal (95% CI) otal events eterogeneity: Chi² = 0. est for overall effect: Z otal (95% CI)	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 41 42 37 39 478 21, df = 1- = 4.72 (P	(P = 0.6 68 30 30 30 38 32 29 34 32 27 31 35 45 42 43 3544 (P = 0.000 69 69 (P = 0.9 0.000 69 10 0.000	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26 14 34 29 34 404 93); I ² = 0% 01)	27 30 38 31 23 34 30 27 31 35 25 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.5% 1.1% 2.1% 1.6% 1.0% 1.0% 1.0% 20.9%	5.04 [0.53, 48.26] 26 4.26 [0.81, 22.53] 20 1.00 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.83 [0.36, 9.12] 20 1.83 [0.35, 5.04] 20 2.13 [0.62, 7.29] 20 2.68 [0.74, 9.73] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 2.55 [0.73, 9.14] 2 2.25 [1.61, 3.15] 2.69 [0.63, 11.49] 20 2.67 [0.74, 9.63] 20	08
otal events eterogeneity: Chi² = 3. sis for overall effect: Z sisplatin (60-80mg/m²) sing, Z.2008 y, Z.2008 y, Z.2009 yen, K.2009 yen, K.2009 yen, K.2009 yen, K.2011 y, Z.2011 y, Z.2011 y, Z.2011 y, Z.2014 y, Z.2014 y, Z.2016 hang, K.2016 hang, K.2016 hang, K.2016 hang, K.2016 hang, K.2016 sing, K.2017 hao, J.2019 ubtotal (95% CI) total events eterogeneity: Chi² = 7. est for overall effect: Z sisplatin (others) y, Y.2012 an, R.2015 ubtotal (95% CI) total events eterogeneity: Chi² = 0. est for overall effect: Z sisplatin (others) y, Y.2012 an, R.2015 ubtotal (95% CI) total events eterogeneity: Chi² = 0. est for overall effect: Z	09, df = 5 = 3.54 (P) 62 29 28 32 27 26 30 29 19 26 31 21 42 37 39 478 21, df = 1. = 4.72 (P	(P = 0.6 68 30 30 30 32 29 34 32 27 31 35 52 55 45 42 43 3541 4 (P = 0.000 69 90 = 0.04)	9); I ² = 0% 4) 56 23 23 32 23 19 28 25 16 22 26 14 34 29 34 404 93); I ² = 0% 53 9); I ² = 0%	27 30 38 31 23 34 30 27 31 35 25 45 42 43 523	0.4% 0.7% 2.3% 1.6% 1.0% 1.1% 2.1% 1.6% 1.3% 1.0% 1.6% 1.4% 20.9%	5.04 [0.53, 48.26] 26 4.26 [0.81, 22.53] 20 1.08 [0.29, 3.43] 20 1.88 [0.54, 6.54] 20 1.82 [0.36, 9.12] 20 1.61 [0.41, 6.30] 20 1.93 [0.42, 8.91] 20 1.63 [0.53, 5.04] 20 2.13 [0.62, 7.29] 20 2.13 [0.62, 7.29] 20 4.53 [1.17, 17.55] 20 3.32 [1.06, 10.37] 20 4.53 [1.17, 17.55] 20 3.22 [1.66, 10.37] 20 2.58 [0.73, 9.14] 20 2.25 [1.61, 3.15] 2.69 [0.63, 11.49] 20 2.67 [0.74, 9.63] 20 2.68 [1.02, 7.01]	08

Figure S93 Subgroups analysis of disease control rate by cisplatin dosage




Figure S94 Meta-regression of disease control rate by cisplatin dosage




Figure S95 Subgroups analysis of neutropenia by cisplatin dosage




Figure S96 Meta-regression of neutropenia by cisplatin dosage




Figure S97 Subgroups analysis of gastrointestinal reaction by cisplatin dosage




Figure S98 Meta-regression of gastrointestinal reaction by cisplatin dosage




Figure S99 Subgroups analysis of objective response rate by evaluation criteria




Figure S100 Meta-regression of objective response rate by evaluation criteria




Figure S101 Subgroups analysis of disease control rate by evaluation criteria




Figure S102 Meta-regression of disease control rate by evaluation criteria




Figure S103 Subgroups analysis of neutropenia by evaluation criteria




Figure S104 Meta-regression of neutropenia by evaluation criteria




Figure S105 Subgroups analysis of gastrointestinal reaction by evaluation criteria




Figure S106 Meta-regression of gastrointestinal reaction by evaluation criteria